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ABSTRACT
Invariant NKT (iNKT) cells are a subset of T lymphocytes that express an invariant 
αβ T cell receptor (TCR) as well as an NK1.1 marker. They play an important role in 
autoimmune diseases, such as type I diabetes and lupus. In contrast to conventional 
CD4+ and CD8+ T lymphocytes that recognise foreign peptides bound to the major 
histocompatibility complex (MHC) class I or MHC class II, iNKT cells recognise a 
range of foreign lipids and glycolipids bound to CD1d proteins. α-Galactosyl 
Ceramide (αGalCer), originally isolated from a marine sponge, is a powerful agonist 
of CD1d capable of triggering an immune response that results in the proliferation of 
a range of regulatory  cytokines, including IFN-γ (Th1), as well as IL-4 (Th2). This 
mixed cytokine response (i.e. Th1 and Th2), combined with the “unresponsive state” 
of iNKT cells after activation with αGalCer, limits the therapeutic potential of this 
agonist. To address some of these issues, we have also synthesised an αGalCer 
analogue, namely  Threitol Ceramide (ThrCer), that exhibits attenuated activity 
relative to αGalCer. ThrCer is a truncated analogue of αGalCer that conserves the 
stereochemistry  of the hydroxyl functions present in αGalCer and that exhibit a much 
stronger ether bond under acidic hydrolysis linking the sugar moiety with ceramide 
than the glycosidic bond in αGalCer. We have labelled ThrCer with a biotin residue 
and with a 14C radiolabel, and our collaborators have used these derivatives to show 
that ThrCer behaves similarly to αGalCer in endogenous lipid trafficking and its 
tissue distribution in vivo. We have also made advances towards the stereoselective 
synthesis of recently discovered natural agonists of iNKT cells from pathogenic 
origin, namely α-galactosyl diacylglycerol (αGalDAG).
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I. INTRODUCTION
1.1. General Introduction.
Immunology has its origins with the discovery, by Edward Jenner in 1796, that 
individuals injected with small amounts of cowpox or vaccinia serum develop 
resistance against smallpox. Edward Jenner called this treatment vaccination and is 
generally  considered the father of immunology after the series of ambitious 
experiments on children in 1796 led to this discovery. Edward Jenner, however, did 
not know the identity of the agents causing the diseases, and it was not until the 
nineteenth century that Robert Koch was able to demonstrate that infectious 
diseases are caused by microorganisms, and that each different invader is capable 
of infesting the host with a different disease or causing a specific pathological 
condition. We group these microorganisms today into four different types according 
to their size, mode of action and constitution: viruses, bacteria, pathogenic fungi, and 
parasites.[1]
Robert Kochʼs discovery stimulated researchers to investigate each pathogenic 
microorganism in the hope of developing a vaccine that could be used for the 
protection against infectious diseases. In the 1880s, Louis Pasteur used this 
approach in his discovery of a vaccine against cholera for chickens, and a vaccine 
against rabies for humans. Shortly  after, in the 1890s, Emil von Behrin and 
Shibasaburo Kitasato found that the serum of animals immune to diphtheria or 
tetanus contained specific proteins, today called immunoglobulins and antibodies, 
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that could give the host short-lived immunity to these diseases. With this discovery, 
Behrin and Kitasato uncovered the adaptive immune response, so called because it 
develops during the lifetime of the individual as an adaptation to the infection of a 
pathogen. In most cases, this leads to a lifelong protective immunity to re-infection 
with the same pathogen.
In contrast to the adaptive immune response, the innate immune response, known to 
us by the work of the great Russian immunologist Eli Metchnikoff, does not require 
prior exposure to the pathogen. This type of immune response acts through 
phagocytic cells, which Metchnikoff called macrophages, that are capable of 
engulfing and digesting the invader.[1] The innate and adaptive immune responses 
compliment each other in the way that if a particular pathogen is not recognised by 
macrophages and successfully invades the host, an adaptive immune response is 
raised to protect the host. If this second line of defence is successful, a record of this 
pathogen and of the specific mechanism of defence is created. If the host is 
challenged in the future with the same pathogen, a faster and more effective adaptive 
immune response is raised. The ability  to remember a pathogen is the pillar of the 
adaptive immune response. The innate immune response cannot remember different 
pathogens because it operates through receptors encoded in the hostʼs genome.[1]
For the fight against the wide range of pathogens that an individual would encounter 
in its lifetime, the immune system circulates molecules throughout the host that are 
capable of detecting, binding, and presenting foreign molecular fragments to the 
immune systemʼs receptors. For example, B cells, which secrete immunoglobulins, 
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with a vast range of antigen specificity. While most immunoglobulins are free to travel 
through the host independently of the parent B cell, some immunoglobulins are 
membrane-bound and act as surface receptors for antigens. These cells with 
membrane-bound immunoglobulins are known as B cell receptors, BCR. An immune 
response is initiated when an immunoglobulin meets with an antigen which is 
presented to BCR, which in turn secretes more immunoglobulins of the same antigen 
specificity, so called antibodies, amplifying the immune response.[1] The main 
function of B cells in the adaptive immune response is to scan the extracellular space 
for signs of invasion, pathogens or their toxic byproducts, and to then mount a 
response that is appropriate in size and type against the particular invader.
In contrast to B cells, T cells scan the surfaces of the organismʼs own cells for signs 
of infection. They recognise debris products of intracellular infection that are 
transported to the cell surface and upon recognition of the antigen are then activated 
to secrete a range of cytokines initiating an immune response. The primary objective 
of the immune response is to remove the specific invader that caused the infection 
selectively.
1.2. The Major Histocompatibility Complex and CD1 Receptors.
The Major Histocompatibility  Complex, MHC, molecules are a specialised class of 
cell glycoprotein capable of binding a large array of small foreign peptides, which are 
produced during a cellular infection. The MHC molecules then present these peptide 
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antigens to T cells, which often results in the cells being marked for destruction, and 
the eradication of the infection.[1, 2]
The MHC molecules are encoded in a large cluster of genes that were first identified 
by their potent effects on the immunological response to transplanted tissues. There 
are two different types of MHC molecules, termed MHC class I and MHC class II, 
which recognise and present peptides from different parts of the cell. Peptides found 
in the cytosol are recognised by MHC class I molecules and presented to CD8 T 
cells, whilst peptides found in intracellular vesicles are recognised by MHC class II 
molecules and presented to CD4 T cells. In turn, the two different subsets of T cells 
are activated and each subset initiates an immune response for destroying the 
pathogen that is resident in the specific cell compartment.
It is suggested that MHC proteins encoded within or near the MHC gene sequence 
are evolutionary and structurally related. MHC class I-like proteins are encoded 
outside the MHC. These families of proteins are related to each other and they all 
have a low level of homology with MHC  class I proteins. These homology studies 
suggested that the three classes of proteins, i.e. MHC class I, MHC class II and MHC 
class I-like proteins, evolved from a common ancestor and that those encoded within 
or near the MHC may have differentiated as the result of evolutionary diversification. 
However, it is apparent that different evolutionary roots distinguished the MHC-linked 
class I-like proteins from its subclass MHC non-linked class I-like proteins.[2-4]
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A hallmark of MHC molecules is the extreme polymorphism that they exhibit. This is 
in strong contrast with the family of Cluster of Differentiation 1, CD1, molecules in 
which there is no evidence for any significant polymorphism. CD1 molecules belong 
to the MHC class I-like class of proteins and are an enigmatic family of proteins that 
present glycolipid antigens to T cells.
Why has the CD1 family of ancient proteins been conserved? Why do they lack 
polymorphism? Why do we need them along with the sophisticated MHC? We cannot 
answer these questions in full at the present time; however a significant amount of 
research has been done that is providing information about the role of this family of 
proteins.[5-9]
The evolutionary origin of the vast polymorphism in MHC proteins is to ensure that 
there are MHC  proteins available across the entire species able to bind and present 
a specific peptide antigen for the necessary immune response against a pathogen to 
ensure the survival of the species. The finding that the protein CD1b is capable of 
presenting glycolipids found in the pathogen Mycobacterium tuberculosis supported 
theories that CD1 proteins may not need to be polymorphic because they present 
bacterial lipids to T cells and because lipids are products of complex biosynthetic 
pathways they evolve much slower than peptides, which means it is less important 
for CD1 proteins to be polymorphic.[10] It was subsequently found that CD1d also 
binds and presents glycolipids to T cells. One such glycolipid is α-galactosyl 
ceramide, αGalCer, which was isolated from a marine sponge.[11, 12] αGalCer binds to 
CD1d and the resulting complex had been shown to be a powerful activator of the 
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immune system leading to the rapid proliferation of interleukin-4, IL-4, and Interferon 
γ, IFN-γ, after activation.[13] A study by Porcelli et al. identified a subset of natural killer 
T cells (iNKT cells) that expresses an invariant T cell receptor, TCR, α chain (Vα24-
Jα18 in humans and Vα14-Jα18 in mice) that was reactive and specific for the CD1d-
αGalCer complex.[14]
Another finding, that currently remains unexplained, is the apparent autoreactivity of 
TCRs with CD1d proteins in the absence of foreign lipids.[15] It is possible that the 
TCR recognises CD1d proteins even when they have no antigen bound although in 
vivo it is improbable that CD1d proteins remain with an empty  hydrophobic pocket in 
an environment where lipids, phospholipids and glycolipids are ubiquitous. This has 
led to the thinking that the TCRs are recognising CD1d proteins with bound self-
lipids, and the possibility  that CD1d proteins may be involved in autoimmune 
responses, which may lead to autoimmune diseases.[16]
CD1 genes in Homo sapiens are expressed only  in certain cells, most commonly  in 
dendritic cells, DCs. We find CD1A, CD1B, CD1C, CD1D and CD1E in Homo 
sapiens; the number of related genes present in other species varies.[17] In mice, for 
example, only two are found, namely  CD1D and CD1E. CD1d proteins are rather 
different from CD1a, -b  and -c proteins, and consequently CD1 proteins have been 
divided into Type I (CD1a, -b, and -c) and Type II (CD1d).[18] CD1e has not been 
placed in either group  yet because so little is known about it. Even though CD1E 
genes are known, the transcribed CD1e protein was not found until 2000.[19] Although 
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this work did not identify a role for CD1e, it showed that CD1e does not behave like 
the rest of the CD1 family of proteins. CD1e is not expressed on the surface of the 
DCs and then internalised like the rest of the family; rather CD1e expressed in DCs 
does not reach the surface and appears to move from the Golgi to late endosomes, 
which suggests that this protein may have a very  different function. Indeed, recent 
work showed that CD1e may act as a helper protein for CD1b  presentation of PIM6 
(hexamannosylated phosphatidyl-myo-inositol) to α-mannosidase.[20]
Structurally, CD1 proteins and MHC class I proteins are only  distantly  related [Figure 
1]. Even though they are both composed of an α strand, divided into α1, α2 and α3 
domains, and a smaller β strand, these domains have low homology.[21, 22] For 
example, the α1 domain of CD1 proteins presents no clear homology  with the α1 
domain of MHC class I molecules. Whilst the α2 domain of CD1 molecules conserves 
all the cysteines which form the intra-domain through disulfide bonds, the overall 
homology with class I molecules is still only 25-35%.[23] The α3 domain is more 
homologous but still quite divergent (45% homology); indeed this domain more 
closely  resembles the β2 domain of MHC class II molecules than it does the α3 
domain of MHC class I molecules, which has led to the suggestion that there was an 
evolutionary force for CD1 molecules to interact with other proteins (the α1 and α2 
domains come together to form a cavity where the antigen can bind, the α3 domain 
and β2 strand are locked away from the binding events and are quite capable of 
interacting with other proteins).[22, 24]
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The binding pockets of CD1 proteins are hydrophobic and are specially  designed for 
binding a large array of lipids. For example, CD1d binds di-alkyl glycolipids into two 
deep hydrophobic pockets, which leaves the polar sugar head group exposed over 
the binding cleft for interactions with TCRs.[14] CD1b molecules have a very deep 
hydrophobic pocket which can hold lipids as large as 80 carbons in length, such as 
those found as components of the cell wall in Mycobacterium tuberculosis.[18, 25-27] 
The exact nature of these hydrophobic tails translates into protein-antigen binding 
affinity, which affects the time that the TCR is in contact with the complex (this is 
important for determining the type of cytokine response). Also, because the ligand 
occupies these large pockets when bound that would otherwise be empty, it affects 
the shape of the complex. The ability to recognise a range of endogenous, 
exogenous and pathogenic lipids and glycolipids, in addition to the large range of 
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Figure 1. Comparison of CD1d protein with one of each class.[22] (A) Showing similarity between 
the α helixes of CD1d with FcRn (MHC Class I-like), H2-K (MHC Class I), HLA-DR1 (MHC Class II). 
(B) and (C) Showing the four proteins superimposed.
peptides recognised by MHC molecules, undoubtedly provides the immune system 
with even more powerful tools for patrolling the cellular environment than was 
appreciated before the discovery of the CD1 family of proteins [Figure 2].
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1.3. α-Galactosyl Ceramide Analogues And CD1d-dependent Bioactivity.
The glycolipid α-galactosyl ceramide, αGalCer, binds with the CD1d protein. The 
resulting complex is recognised by TCRs located on iNKT cells and this leads to the 
development of helper T cells type 1, named a Th1 response, and also to the 
development of helper T cells type 2, named a Th2 response.[6, 28] The rapid 
response of the immune system by activation of iNKT cells via CD1d presentation 
makes this protein of unique importance with potential application in the treatment of 
cancer, malaria, as well as various autoimmune diseases.[8] αGalCer is the most 
powerful antigen yet discovered for CD1d in terms of the immune response it 
precipitates. However since this response is both pro-inflammatory and regulatory, 
αGalCer is an unlikely drug. The majority  of recent research efforts for understanding 
these activation events and for developing possible therapeutic agents have been 
based on αGalCer analogues.
The crystal structure of the CD1d-αGalCer complex has been described [Figure 3].[29] 
It was found, as expected, that the hydrophobic tails of αGalCer are buried into the 
two hydrophobic pockets, designated A' and C'. The acyl chain, 26 carbon atoms in 
length, fits optimally into pocket A' while the phytosphingosine, 18 carbon atoms in 
length, occupies the smaller pocket C'.
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Figure 3. The X-ray crystal structure of the CD1d-αGalCer complex.[29]
The optimum length of the two hydrophobic tails of αGalCer 1 for binding to CD1d 
explains the selectivity of CD1d for ligands possessing relatively  short hydrophobic 
chains, 12 to 26 carbon atoms in length [Figure 4]. Mammalian glycosphingolipids 
and ceramide phospholipids have a maximum length of 24 carbon atoms in the acyl 
chains, and for glycosphingolipids, the sphingosine is usually  20 carbon atoms in 
length.[15] In the X-ray crystal structure study,[29] the authors suggested that ligands 
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with hydrophobic tails longer than those of αGalCer will not fit into the CD1d groove 
correctly and will not, therefore, be optimally  supported by the hydrophobic 
interactions with the amino acid residues in the pocket. Likewise, ligands with shorter 
chains might still bind to CD1d but with reduced binding affinity.
O
HO
HO
OHO
OH
HN
OH
OH
O
1, αGalCer
Figure 4. α-Galactosyl ceramide.
αGalCer also tolerates substitution on the sugar moiety allowing for the identification 
of active galactosyl sulfatides[30] and a variety of polyglycolipids as CD1d antigens.[31] 
This diversity in tolerated substitutions on the sugar moiety is not matched with 
diversity in activity. In fact, the activity of most sugar-substituted analogues of 
αGalCer is similar in type to the parent compound. A more diverse immune response 
is found when the lipid tail of the molecule is modified, which provided us with a 
strategy for tuning the immune response; however, in most cases the immune 
response is still mixed, i.e. regulatory and pro-inflammatory, which continues to 
restrict the therapeutic applications of such analogues. For example, it has been 
demonstrated that the effect of reducing the lipid chain length in the 
phytosphingosine component is to increase the amount of IL-4 (regulatory response) 
versus IFN-γ (pro-inflammatory response) being produced.[32]
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Although it has been demonstrated that αGalCer is an effective and very powerful 
activator of the immune system, it has also been found that after a single activation 
event with αGalCer, iNKT cells display a long period of anergy during which iNKT 
cells population diminish to nearly undetectable levels and are unresponsive when 
pulsed with further doses of αGalCer.[33] It was postulated that anergy is the result of 
a too powerful activation, which induces a process in which the iNKT cells deepen 
their surface receptors to avoid further activation. This lack of reactivity lapses over 
two weeks after a single stimulation; it is a major problem for the possible therapeutic 
applications of αGalCer and must also be taken in consideration when designing new 
αGalCer analogues for activation of iNKT cells, i.e. analogues which are less 
powerful activators of iNKT cells and which induce shorter anergy periods are 
preferable for therapeutic applications.
The hydrophobic tails of αGalCer are an obvious target for the fabrication of new 
analogues. Many modifications in these parts of αGalCer can change the nature of 
the hydrophobic interactions with the binding pockets of CD1d [Figure 5]. For 
example, Miyamoto et al. synthesised a truncated analogue of αGalCer with 24 
carbon atoms in length as the acyl chain and a phytosphingosine with nine carbon 
atoms in length, compound 2.[32] Like αGalCer, this compound, which they named 
OCH, was also found to stimulate iNKT cells by way of CD1d and induced an 
immune response with a Th2 bias. In a separate study, Oki et al. synthesised various 
analogues of αGalCer possessing different sphingosine lengths and demonstrated 
that the production of IFN-γ is more susceptible to the length of the phytosphingosine 
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base than is the production of IL-4.[34] The authors postulated that the shorter 
sphingosine length destabilises the CD1d-αGalCer complex because of a reduction 
in the ligandʼs overall hydrophobicity, which therefore reduces the time that the 
complex is in contact with the TCR. This observation led to the conclusion that a 
longer exposure to the TCR is required to induce higher levels of IFN-γ.
Toba et al. explored other modifications on the phytosphingosine and compared 
these new analogues to OCH. They found that in compound 3 [Figure 5], while this 
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Figure 5. Examples of synthetic αGalCer analogues.
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molecules still features a short sphingosine chain, the hydrophobicity has been 
increased with respect to OCH by introducing a phenyl substituent. As a result, 3 is 
capable of inducing larger amounts of IL-4 and IFN-γ than OCH.[35] The response 
displayed by 3 is still a Th2 bias in the cytokine response although this is less 
pronounced than that observed with OCH.
In another study, which focused on the effects of varying the hydrophobicity  of the 
acyl chain, it was found that aromaticity in this part of the molecule can also influence 
the cytokine profile of the immune response. For example, compound 4 was found to 
be optimal for inducing a higher production of IFN-γ in vitro and was also capable of 
producing abundantly a range of cytokines typical of a Th1 immune response in vivo.
[36] Interestingly, in another report, compound 5, which contains an arachidonic acid 
acyl chain, was found to favour a Th2 response.[37] The pattern emerging for the acyl 
chain seems to point to short aromatic substitutions favouring the preferential 
production of Th1 cytokines while heavily  unsaturated acyl chains favour the 
production of Th2 cytokines [Figure 5].
The C-glycosyl analogue of αGalCer, compound 6, is another glycolipid which was 
found to produce a Th1-biased immune response. In this analogue, the hydrolytically 
labile glycosidic bond of αGalCer is replaced with a much stronger carbon-carbon 
bond.[38-40] Consequently  this compound is expected to survive a wider range of 
conditions for a longer time than is αGalCer, which can therefore increase the time 
that CD1d can present this αGalCer analogue to the TCR. This is another example 
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where the analogue suspected of increasing presentation time induces a Th1-biased 
immune response.
The disaccharide 7 was used as a probe to demonstrate that although some 
disaccharides can be presented for recognition to TCRs without lysosomal 
processing, this example required removal of the second galactose moiety before it 
can be recognised by TCRs [Figure 5].[41, 42] This constitutes an example of a 
carbohydrate antigen processing mechanism and an ability for iNKT cells to 
recognise smaller fragments of complex glycolipids.
1.4. Syntheses of α-Galactosyl Ceramides.
α-Galactosyl ceramides were first found in the natural world by Natori et al. who 
isolated them from the marine sponge Agelas mauritianus.[43] A range of 
glycosphingolipids were isolated, with most possessing an α-galactosyl ceramide 
structures that were acylated with an alpha hydroxy fatty acid of 26 and 24 carbons in 
length. In another paper published simultaneously, Natori et al. presented the 
synthesis of agelasphin-9b to confirm the absolute and relative stereochemistry of 
the isolated sphingolipid.[44] The key retrosynthetic steps are outlined below [Scheme 
1].
Introduction
16
The retrosynthetic analysis identified the glycosidic bond as the first disconnection 
revealing a suitably protected ceramide moiety 9 as the acceptor and perbenzylated 
galactosyl fluoride 8 as the sugar donor. The amide bond in the ceramide acceptor 
was further disconnected and the synthetic equivalents were identified as the p-
nitrophenylester 10 and the corresponding suitably protected phytosphingosine 11. 
This retrosynthetic analysis benefits form a late-stage glycosylation step, requiring 
only two further deprotection steps to reach the synthetic target.
Scheme 1. Retrothesis of α-galactosyl ceramide agelasphin-9b.
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In the forward synthesis [Scheme 2] the amine 11 was reacted with the p-
nitrophenylester 10 in THF to provide the target amide in 40% yield. Natori et al. did 
not offer an explanation for the moderate yield of this reaction; however, it is possible 
that a side-reaction involving intramolecular migration of a benzoate group on to the 
neighbouring amine might be responsible for the low yield of product 9. In spite of the 
low yield, Natori et al. were able to proceed to the glycosylation step with the 
perbenzylated galactosyl fluoride sugar donor 8. The use of perbenzylated glycosyl 
fluoride 8 as a sugar donor in a glycosylation reaction was first reported by 
Mukaiyama et al.[45] Activation of the donor with SnCl2/AgClO4 provided the α-
glycoside preferentially: a range of alcohol acceptors including sterically  hindered 
Scheme 2. Key stereoselective glycosylation yields agelasphin-9b's precursor 12.
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alcohol acceptors like 2,3,6-tri-O-benzyl-α-D-glucopyranoside, cholesterol and 3β-
cholestanol, all afforded favourable α:β ratios of the glycoside products in high yields. 
However, Natori et al. did not obtain a high yield in the glycosylation reaction 
involving donor 8 with the ceramide acceptor 9. Although they did not comment on 
the reaction efficiency, we can hypothesise that intramolecular H-bonding between 
the amide and the free hydroxyl renders the acceptor a poorer nucleophile and may 
account for the low efficiency of this reaction [Figure 6].
Nevertheless, Natori et al. obtained the desired glycoside product 12 as a single 
anomer and recovered 40% of the unreacted acceptor 9. The product 12 was then 
subjected to hydrogenolysis with H2 and Pd (black) as catalyst for the deprotection of 
the benzyl groups, affording 13, followed by removal of the two type of ester 
protecting groups under basic conditions to afford the target agelasphin-9b [Scheme 
3]. Although Natori et al. did not report the yields of these final two deprotection 
steps, it is reasonable to assume that both steps were efficient and given that the 
sugar donor 8 is relatively easily accessible, this is an attractive first stereoselective 
route to α-galactosyl ceramides. 
HO
OBz
OBz
21
N
O
OAc
H
Intramolecular H-bonding
Figure 6. Intramolecular H-bonding in ceramides.
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In another approach to these molecules, Figueroa-Perez et al. chose to install the 
fatty  acid after the glycosidation step, which would allow them to explore a range of 
different acceptors [Scheme 4].[46] Specially, they had in mind two different triols 16 
and 17 as acceptors. Triol 16 possesses a methanesulfonate leaving group that 
could be displaced in an SN2 reaction with a nucleophilic source of nitrogen (i.e. 
azide) to yield the required intermediate 14 after glycosidation with the donor 15 
[Scheme 4]. Alternatively, triol 17 which carries the N3 already would yield 14 directly 
after the glycosidation step. Figueroa-Perez et al. identified synthetic routes from a 
common galactose derivative 18 from which both the sugar donor and the acceptor 
triols would be synthesised.
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Scheme 3. Chemoselective deprotection sequence yields agelasphin-9b.
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The triols 16 and 17 were prepared from the galactose derivative 18 in five and six 
steps, respectively. Aldehyde 19 was obtained by oxidative cleavage of 18 with NaIO4 
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Scheme 4. Schmidt retrosynthetic analysis of αGalCer.
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[Scheme 5]. The addition of alkyl Grignard reagents to aldehyde 19 had been studied 
previously,[47] where it had been observed that in the presence of the chelating Lewis 
acid TiCl4, only the required diastereoisomer is obtained in high yield. It was then 
possible to install the methanesulfonate leaving group chemoselectively in the less 
hindered alcohol in diol 20. The acetal in the product 21 was then selectively 
hydrolysed in acidic methanol [Scheme 5]. The triol 16 was then converted in to triol 
17 by a displacement reaction of the methanesulfonate with tetramethylguanidinium 
azide,TMGN3, in DMF [Scheme 5].
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Scheme 5. Synthesis of azido-phytosphingosine 17.
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The sugar donor 15 was also prepared from the triol galactose derivative 18 [Scheme 
6]. Triol 18 was first treated with one equivalent of NaH and allyl bromide, which 
preferentially  reacted with the hemiacetal alcohol to provide an allyl glycoside, which 
was subsequently treated with two further equivalents of NaH and benzyl bromide to 
yield the fully protected sugar 22 [Scheme 6]. The allyl group was chemoselectively 
deprotected with PdCl2 and the resulting hemiacetal 23 was converted into the 
trichloroacetimidate sugar donor 15 on reaction with DBU and trichloroacetonitrile 
[Scheme 6]. The key  glycosylation was carried out at -10 °C in THF with both 
acceptor triols 16 and 17. The desired glycoside products 24 and 14 were obtained 
by the chemoselective reaction of the primary alcohol in the presence of two 
secondary alcohols with the activated donor [Scheme 6]. Figueroa-Perez et al. found 
that the glycosidation with acceptor triol 16 afforded product 24 in high yield, while 
with acceptor triol 17 the glycosidation afforded a mixture of products from which the 
desired glycoside 14 could be isolated in low yield.
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The methanesulfonate leaving group  in glycoside 24 was then displaced with 
inversion of configuration with TMGN3 in DMF to afford 14 in high yield [Scheme 7]. 
The benzyl protecting groups, the benzylidene and the azide were hydrogenolysed 
with H2 in the presence of catalytic amount of Pd/C and the fully  deprotected amide 
was acylated with cerotic acid by reaction with N,N'-dicyclohexylcarbodiimide, DCC, 
and employing hydroxybenzotriazole, HOBt, as a nucleophilic catalyst, to afford 
αGalCer 1.
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Scheme 6. Stereoselective synthesis of glycoside 24 and 14.
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In another example of α-galactosyl ceramides synthesis, Gervay-Hague and co-
workers have employed a perbenzylated galactosyl iodide as the sugar donor 
[Scheme 8].[48] The highly reactive, and prone to hydrolysis, sugar donor 26 was 
prepared in situ from 25 by treatment with trimethylsilyl iodide, TMSI. The resulting α-
galactosyl donor 26 was then treated with an excess of tretrabutylammonium iodide, 
TBAI, to establish an equilibrium with a small amount of the more reactive β-
galactosyl donor 27, which reacts with the acceptor alcohol 28 in an SN2 fashion to 
yield exclusively the α-galactoside product 29 in high yield. The azide was then 
reduced to the amine 30 with hydrogen sulfide and pyridine, which was subsequently 
acylated to afford amide 31. Finally, hydrogenolysis of the benzyl and p-
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Scheme 7. Synthesis of αGalCer 1 from 24.
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methoxybenzyl protecting groups present in 31 yielded α-galactosyl ceramide 32 
[Scheme 8].
Although Gervay-Hague and co-workers successfully synthesised α-galactosyl 
ceramide employing perbenzylated galactosyl iodide, the method was limited to the 
synthesis of saturated ceramides since they relied on the global deprotection of the 
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Scheme 8. Stereoselective synthesis of α-galactosyl ceramide 32.
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benzyl and p-methoxybenzyl groups by hydrogenolysis, which is incompatible with 
ceramides possessing unsaturation. Gervay-Hague and co-workers addressed this 
issue in the same publication.[48] They discovered that the persilylated galactose 33 
can be converted quantitatively into the persilylated galactosyl iodide 34 by reaction 
with TMSI, and that this reacts smoothly under the conditions established previously 
for perbenzylated galactosyl iodide with acceptor 35 and with complete selectivity for 
the α-anomer yielding galactoside 36 [Scheme 9].
Although all methods for the synthesis of α-galactosyl ceramides described here are 
similar, crucially they differ in the glycosylation conditions employed to achieve 
stereoselectivity and the stage when to install the fatty acid, before or after the 
glycosylation step. Gervay-Hagueʼs method that employs the persilylated galactosyl 
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Scheme 9. Gervay-Hague's stereoselective α-galactosylation.
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iodide as sugar donor yielding the deprotected sugar directly after acidic treatment is 
considered the most attractive method. It is not only a short stereoselective route to 
α-galactosyl ceramides in which the reactive sugar donor is quantitatively made in 
situ from trivially  accessible persilylated galactose but also permits to carry 
unsaturations in the sphingosine base which is forbidden in other methods when the 
deprotection strategies rely on hydrogenolysis [Scheme 9].
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II. AIMS AND OBJECTIVES
From a synthetic view point, αGalCer presents us with a number of challenges. 
Although the molecule possesses various stereogenic centres, these can mostly be 
bought in from natural sources, namely galactose and phytosphingosine, which are 
available commercially as single enantiomers. However, the α-galactosidic bond is a 
relatively difficult bond to make stereoselectively and this aspect of the synthesis in 
particular needs careful planning. The alcohols need to be appropriately protected 
before the fragments can be put together. These protecting groups then need to be 
removed at a later stage, which further extends the length of the synthesis and 
increases likelihood of encountering problematic steps.
It should also be noted that the glycosidic bond in αGalCer can be relatively easily 
degraded in a biological environment, not only by  the possible presence of α-
galactosidases but also by hydrolysis in the acidic cellular media where αGalCer may 
be delivered.
In a recent study it was discovered that replacing the galactosyl polar-head group 
with a truncated galactose moiety addressed some of the problems associated with 
αGalCer, including the long period of anergy after a single activation and the 
propensity to induce iNKT cell-dependent lysis of DCs.[49] The analogues were 
arabinitol ceramide, AraCer, threitol ceramide, ThrCer, and glycerol ceramide, GlyCer 
[Figure 7].
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Although GlyCer and AraCer analogues stimulate iNKT cells with varying success it 
was found that ThrCer was an accomplished analogue of αGalCer. ThrCer stimulates 
iNKT cells and induces the secretion of IFNγ and IL-4 with a similar profile over time 
as αGalCer activation, but only half the amount of cytokines are produced. As a 
consequence, it was also found that iNKT cells recovered from anergy  14 days after 
a single activation with ThrCer, whereas no stimulus was found after the same time 
when iNKT cells were activated with αGalCer. The three analogues were also 
assayed for their ability  to control tumor growth and of the three, only ThrCer was 
able to suppress tumor growth after 14 days. Structurally, ThrCer is a truncated 
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Figure 7. Truncated derivatives of αGalCer.
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version of αGalCer where the C(5) and C(6) atoms have been excised from the 
hexose sugar [Figure 8].
This modification was proposed by analysis of the X-ray crystal structure of the 
CD1d-αGalCer-TCR complex,[50] which pointed to the OH groups on C(2), C(3) and 
C(4) being essential for the recognition of the CD1d-αGalCer complex by  TCRs 
through H-bonding [Figure 9]. Since the hydroxyl at C(6) was not observed to 
participate in H-bonding with either CD1d or with the TCR, this suggested that its 
deletion may not be detrimental for TCR recognition of the CD1d-αGalCer complex, 
which proved to be the case.
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Figure 8. ThrCer is a truncated analogue of αGalCer.
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Figure 9. Important H-bonding interactions for recognition were revealed in studies of the X-ray crystal 
structure of CD1d-αGalCer complex and of CD1d-αGalCer-TCR complex. The primary hydroxyl of 
galactose and the anomeric oxygen (highlighted in red) are not involved in H-bonding interactions with 
neither the TCR or CD1d.
ThrCer also possesses the advantage over αGalCer, that the polar head group  is 
bound to the ceramide base via an ether bond, which is more stable towards acidic 
hydrolysis and biodegradation than the glycosidic bond of αGalCer. This increased 
stability should extend the time that ThrCer persists in the cell compartments, 
increasing the chances of it being loaded on to CD1d for presentation. The ether 
bond not only confers increased stability  to ThrCer but also makes the molecule an 
easier synthetic target, removing the requirements for exercising a difficult α-
stereoselective glycosylation.
Schmidt and co-workers synthesised ThrCer from commercially  available building 
blocks.[51] The key steps of their synthesis are outlined below [Scheme 10]. The key 
etherification was performed by treating the phytosphingosine derivative alcohol 41 
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with NaH and reacting the resulting alkoxide with a suitably protected threitol 
derivative, triflate 42. Under these conditions, Schmidt and co-workers reported that 
no elimination byproducts were formed and the ether product 43 was obtained in very 
high yield. Simultaneous deprotection of the benzyl ethers protection and the azide 
under hydrogenation conditions yielded 44, which was chemoselectively acylated to 
provide amide 45. The isopropylidenes were then removed by treatment with TFA in 
MeOH to provide the target ThrCer 39 [Scheme 10].
In our lab  we wanted to develop a more general and divergent synthetic route to 
ThrCer 39 exploiting protecting groups that could be removed orthogonally and allow 
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Scheme 10. Schmidt's synthesis of ThrCer.
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selective access to the different hydroxyl groups for diversification. In particular, we 
were interested in accessing selectively the internal diol in the threitol moiety for 
further elaboration (for example for glycosidation with a suitable galactosyl or 
mannosyl donor), which in Schmidt and co-workersʼ synthesis is protected with an 
isopropylidene analogously to the internal diol of the phytosphingosine. 
Consequently, hydrolysis of one isopropylidene in 43 will necessary  result in the 
hydrolysis of the other isopropylidene [Scheme 10]. We identified the intermediate 46 
as our key divergent intermediate [Scheme 11]. The intermediate 46 carries a 
benzylidene protecting group in the threitol moiety  that can be reductively opened 
with DIBAL-H or removed by hydrogenolysis to reveal the internal diol in the threitol 
moiety which can be subsequently  glycosylated [Scheme 11]. The silyl protecting 
group can also be selectively  removed with a fluoride source l ike 
tetrabutylammonium fluoride, TBAF, and the resulting alcohol can then also be 
glycosylated, scheme 11, giving access to other glycosylated ThrCer derivatives. 
These are important modifications of ThrCer with speculative bioactivity of interest to 
our collaborators and us and we were interested to access them at later time.
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Furthermore, we required that our synthetic route would also allow us to install the 
fatty  acid as the last step, which would facilitate a proposed synthesis of 14C radio-
labelled ThrCer by minimising the number of synthetic steps we would need to 
perform on radio-labelled material. For this reason we identified 47 as the key late-
stage precursor of ThrCer [Figure 10].
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Figure 10. Key late-stage ThrCer precursor.
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Scheme 11. Highly divergent intermediate 46 offer access to ThrCer derivatives.
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In another vein, α-galactosyl diacylglycerols, αGalDAGs, of pathogenic origins are 
natural glycolipids and were recently  shown to be agonists of CD1d that are capable 
of inducing cytokine production in both mouse iNKT cells and human iNKT cells.[52] 
Initial studies have shown that their activity is closely related to the structure of the 
acyl chains. Our research group, in collaboration with Prof. Michael Brennerʼs group 
at the Brigham and Womenʼs Hospital in Boston at Harvard University, wanted to 
develop a reliable and scalable selective synthesis of αGalDAG that would allow the 
synthesis of a range of αGalDAG analogues to study their potential as therapeutic 
agents.
✦ Aims and objectives:
1. Novel and divergent synthesis of ThrCer.
2. Synthesis of biotin- and 14C-labelled ThrCer.
3. Stereoselective synthesis of αGalDAG.
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Figure 11. α-Galactosyl diacylglycerol, αGalDAG, from pathogenic origin can activate iNKT cells.
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III. SYNTHESIS OF THREITOL CERAMIDE AND LABELLED ANALOGUES
3.1. Synthesis Of Threitol Ceramide.
The retrosynthesis of ThrCer 39 is outlined in scheme 12. In our analysis we 
identified two commercially available starting materials, diol 51 and phytosphingosine 
52, that could be converted into two reactive partners, 49 and 50, uniting these two 
fragments via an etherification. The ether 48 could be taken through to amine 47 in 
two steps; thus acidic hydrolysis of the acetal and ketal groups would reveal the 
pentaol, leaving the azide which can be reduced under hydrogenolysis conditions. 
The amide coupling that follows could be easily achieved on activation of cerotic acid 
with a carbodiimide coupling reagent or other activated carboxylic acid derivative to 
provide the target ThrCer 39.
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The starting protected threitol moiety 51 carries the benzylidene acetal as a 
protecting group for the internal 1,2-diol. This protecting group introduces an 
additional stereocentre, which means that all asymmetric derivatives of 51 carrying 
this protecting group will be obtained as a mixture of diastereoisomers. Although this 
choice of protecting group would add complexity to the characterisation of the 
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Scheme 12. Retrosynthetic analysis of ThrCer 39.
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intermediate products, it would also add a degree of flexibility to the synthesis as this 
protecting group can be removed by hydrogenolysis and by acidic hydrolysis.[53] We 
chose a bulky TBDPS ether group to protect one of the remaining primary alcohols 
[Scheme 13], foreseeing the basic, and nucleophilic, conditions of the ether bond 
synthesis that lay  ahead. Unhindered silyl ethers are susceptible to nucleophilic 
attack and therefore are generally not stable in the presence of an alkoxide;[54] 
however, bulky silyl ether protecting groups like TBDPS and TIPS are much more 
stable to these reaction conditions. The silyl group  protecting this terminal OH is also 
an orthogonal protection that would allow us to elaborate through this end at a later 
stage should this be necessary, for example if we wanted to glycosylate ThrCer 
through the primary alcohol. The pseudo C2-symmetry in 51 means that a simple 
mono-protection of the diol was all that was needed to get us through to compound 
53 which was achieved following the Schmidt approach with the sodium alkoxide and 
the TBDPS chloride in THF [Scheme 13].[51] The diastereoisomeric of silyl ethers 
mixture was confirmed by the presence of two singlets at 1.07 and 1.09 ppm in the 
1H NMR spectrum, each the nine protons of the tert-butyl group in the 1:1 mixture of 
diastereoisomers of 53.
We chose to convert alcohol 53 into an electrophile for the subsequent etherification 
[Scheme 13]. Of course, we could make the alkoxide from this alcohol and the 
electrophile on the phytosphingosine fragment and would return to this choice if the 
proposed etherification failed. Alcohol 53 can be converted into an array of suitable 
electrophiles. Alkyl bromides and alkyl iodides are often employed in ether bond 
formation reactions.[55] Alkyl bromides can be conveniently prepared directly from 
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alcohols by reaction with Ph3P and CBr4, while alkyl iodides are more efficiently 
made in two steps often involving conversion of the alcohol into a tosylate leaving 
group,[56] followed by subsequent displacement with a source of iodide, usually NaI in 
acetone. Sulfonates, like tosylates and mesylates, are easily prepared from alcohols 
in one step, and are themselves also commonly  employed as leaving groups in 
nucleophilic substitution reactions, including etherifications.[57-59]
In this ether synthesis, we chose to convert our alcohol into a sulfonate, scheme 13, 
in line with the literature and taking in consideration that triflates are very good alkyl 
electrophiles,[51] owing their high electrophilicity to three strongly electron-withdrawing 
fluoro substituents. The pKa of triflic acid is estimated to be around -14 in water 
making it one of the strongest acids commonly used in organic chemistry.[60] Such a 
low pKa tells us that the conjugate base need not be in contact with a counter ion and 
can exist as a separate solvated entity; this is what defines a good leaving group. A 
potential disadvantage of alkyl triflates though, is that they can decompose rapidly 
before they can be used in a following displacement reaction. The decomposition 
pathway usually involves elimination reactions that yield the alkene, or rupture of the 
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Scheme 13. Synthesis of orthogonally protected triflate 49.
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C-OTf bond, which leaves behind a highly  reactive cation that decomposes in 
undetermined reactions.
Alkyl triflates are usually  prepared from the corresponding alcohol by reaction with 
triflic anhydride in the presence of an excess of pyridine which functions as an acid 
scavenger.[61] In our synthesis of triflate 53, we found that although TLC  analysis 
showed that the triflate formed readily, it rapidly decomposed when pyridine was 
used as the acid scavenger. We thought that the pyridine was perhaps causing the 
decomposition of our alkyl triflate. Pyridine can act as a nucleophile, and; in some 
cases, pyridine is strong enough a base to induce elimination of the triflate;[62] both of 
these reaction pathways would lead to the decomposition of the alkyl triflate. In line 
with Schmidt and co-workers report,[51] we then employed a hindered pyridine base, 
DTBMP, and TLC analysis showed that the triflate was formed quantitatively and 
instantaneously after the dropwise addition of triflic anhydride to a solution of the 
alcohol in CH2Cl2 [Scheme 13]. Considering its instability, the alkyl triflate 53 was 
used directly without purification in the key etherification reaction. Attempts to purify 
this triflate by flash column chromatography resulted in considerable losses of 
material and low overall yields although Schmidt and co-workers had reported good 
overall yields in their approach that includes a purification of a similar triflate by flash 
column chromatography [Scheme 13].[51]
The nucleophilic reacting partner for the etherification was prepared from 
commercially available phytosphingosine, which was first converted quantitatively to 
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the azido protected form 54 employing a methodology developed by Wong and co-
workers [Scheme 14].[63, 64]
This methodology requires the efficient preparation of a solution of TfN3 with 
sufficient purity and concentration for using in the N2 transfer reaction. Wong et al. 
identified an array of transition metal salts that can catalyse the azidation; the 
reaction did not proceed in the absence of the metal catalyst. The best catalysts 
proved to be ZnCl2 and CuSO4. Although the reaction time when CuSO4 was 
employed was considerably  longer (18 h) in comparison with ZnCl2 (2.5 h), the use of 
the copper catalyst proved to be effective for a larger range of substrates and was 
our first choice of catalyst.
We considered protecting the amine in 52 as an azide superior to using a carbamate, 
which is another common class of protecting group  for the amine functionality. For 
Scheme 14. Synthesis of protected azido alcohol 56.
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example, Boc, Cbz and Fmoc carbamates are all commonly  employed as protecting 
groups for amines.[65] However, carbamate protecting groups can be easily 
deprotonated with a strong base like NaH, which we required for the formation of the 
alkoxide 50 for our etherification. Although the alkoxide is expected to be a better 
nucleophile than the carbamate anion on steric and pKa grounds,*  the use of a 
carbamate protecting group could render the etherification more difficult and afford 
lower yields due to competing N-alkylation and elimination reactions. The azide also 
gives us the opportunity to carry out a stepwise deprotection of the ether 46. 
Protecting group orthogonality was not a requirement for the synthesis of ThrCer but 
it might be an advantage at later stage were we might need to prepare more complex 
substrates. We also compared the azide to the phthalimide as another protection 
strategy for amines; although the latter can also be orthogonally deprotected under 
nucleophilic conditions, there were no literature examples for the protection and 
deprotection sequence of the phytosphingosine with phthalimide but there were 
many examples of azide protection being used effectively on phytosphingosine 
substrates.[46, 48, 66] The protection of the amine in phytosphingosine 52 as an azide 
under Wongʼs conditions provided 54 in very high yield and was readily  confirmed by 
the appearance of a peak at 2108 cm-1 in the IR spectrum of the product 54, 
corresponding to the characteristic azide stretch. The product was also confirmed by 
MS [Scheme 14].
The next step required the selective protection of the two secondary alcohols in 54 to 
leave the primary alcohol ready for etherification. The choice of protecting groups 
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*The primary alcohol should be less sterically hindered than the carbamate; the pKa of a primary alcohol is 
estimated around 16 while that for a carbamate NH is estimated around 12.
should allow easy deprotection and because we would already  have an acetal in the 
threitol fragment, another acetal or ketal would conveniently minimise the number of 
deprotection steps and therefore seemed to be a sensible first choice.
The selective protection of 1,2-diols when 1,3-diol protection is also possible, as in 
our case, is usually achieved by employing a ketal protecting group, commonly an 
acetonide. Selective protection is possible because of the relative thermodynamic 
stability of the possible ring products. Acetal and ketal formation is a reversible 
process that can lead to high levels of selectivity in favour of the thermodynamic 
product. Protection of a 1,3-diol with an acetal generates a six-membered ring 
dioxane product. In this case, acetals derived from aldehydes such as benzylidenes 
are more thermodynamically  stable than the corresponding 1,2-diol acetals, which 
generate a five-membered dioxolane ring, because the acetal substituent can be 
placed in an equatorial position in the six-membered ring thereby minimising 1,3-
diaxial interactions. When the protection is performed with a ketone, however, the 
resulting five-membered ring ketal is more stable because the 1,3-trans diaxial 
interactions present in the six-membered ring products resulting from 1,3-diols, are 
destabilising.
When we attempted to selectively  protect the 1,2-diol in triol 54 in acetone containing 
a sub-stoichiometric amount (10 mol%) of pTSA, we obtained a mixture of products. 
1H NMR analysis revealed that the desired 1,3-dioxolane was the major compound in 
a ratio of 4:1 with the minor 1,3-dioxane product as evidenced in the 13C NMR 
spectrum showing a CH2 peak at 25 ppm corresponding to the two methyl 
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substituents of the ring. The purification of the desired major product from this 
mixture was achieved by column chromatography only on small scale (100 mg).
An improved and scalable method was to treat the triol with sub-stoichiometric 
amounts (5 mol%) of Sc(OTf)3 in a 1:1 mixture of acetone/2,2-dimethoxypropane 
[Scheme 14].[67] This method afforded a mixture of acetals 55 and 56. Pure 56 was 
then obtained by selectively hydrolysing the more labile acyclic acetal in 55 under 
mild acidic conditions. The desire protection pattern in the product 56 was confirmed 
by analysis of the 13C  NMR sprectrum that showed the isopropylidene methyl groups 
as two resonances at 25.5 ppm and 28.0 ppm, which is characteristic of a five-
membered ring isopropylidene protected anti-1,2-diol [Scheme 14].
With the two suitably protected reacting partners in hand, the etherification 
proceeded smoothly  on treating the sodium alkoxide 50 with triflate 49 at 0 °C in line 
with the Schmidt synthesis [Scheme 15].[51] The product 46 was confirmed by 
obtaining accurate mass spectral and spectroscopic data, wich provided evidence for 
the benzylidene acetal showing two singlets in the 1H NMR spectrum at 5.95 and 
6.00 ppm, and in the 13C NMR spectrum two resonances at 25.6 and 25.7 ppm plus 
another two at 28.1 and 28.2 ppm, corresponding to the two methyl groups of the 
isopropylidene 1,2-diol protecting group. The ether 46 was then desilylated using 
TBAF as a fluoride source [Scheme 15]. The resulting alcohol 48 is an important 
intermediate that can be used, for example, as a suitably protected acceptor in future 
studies where ThrCer may need to be glycosylated. The alcohols 48 was confirmed 
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by high resolution mass spectrometry, HRMS. The NMR data of 48 was also 
consistent with the removal of the silyl ether protecting group.
We deprotected the acid-labile acetals in 48 employing 30 mol% of Ce(OTf)3 per 
acetal in a solution of MeNO2 saturated with water following a literature procedure 
[Scheme 16].[68] The reaction was complete after two hours, as judged by TLC 
analysis. When we attempted to isolate the polyol product, we found that aqueous 
work-up produced emulsions resulting in considerable loss of material. Since this 
deprotection step was high yielding, we reasoned that instead of isolating this pentaol 
we could reduce the crude azide by hydrogenolysis, hoping that the Ce(OTf)3 Lewis 
acid and triflate salt that might be present in the crude starting material would not 
interfere with the reduction.
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ii) 49
TBAF
THF
HO
N3
O
O
13
56 46, 92%
48, 95%
Scheme 15. Synthesis of intermediate azide 48.
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The hydrogenolysis of the crude azido-pentaol resulting from the acetal hydrolysis 
using Pd/C in acidic MeOH was monitored by TLC. The reaction progressed over 
four hours by which time TLC analysis showed that all the starting azide had been 
consumed [Scheme 16]. After filtering off the charcoal and evaporating the volatiles 
under reduced pressure, a solution of the crude amine 47 was prepared in THF (0.1 
M, based on starting azide 48 and assuming 100% conversion for the deprotection 
sequence) and used in the next step without purification.
Acyl chlorides are commonly prepared by reacting the corresponding carboxylic acid 
with an excess of oxalyl chloride in CH2Cl2 at 0 °C employing DMF as a nucleophilic 
catalyst.[69, 70] However, we had in mind to transfer this methodology to the synthesis 
of 14C-labelled ThrCer and were doubtful this approach, which introduces DMF, would 
be amenable to the very small scales that we would be employing for the synthesis of 
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Scheme 16. Synthesis of ThrCer from fully deprotected amine 39.
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14C-labelled ThrCer. We, therefore, adopted what we considered would be a more 
reliable methodology in which cerotic acid was heated in a solution of oxalyl chloride 
at 70 °C  for two hours after which time the reaction mixture was brought to r. t. and 
the volatiles were evaporated under reduced pressure to provide the acyl chloride 
which was used immediately in the amidation reaction with amine 47. In this way the 
target ThrCer 39 was obtained in good yield after purification by silica gel 
chromatography [Scheme 16]. The product 39 was confirmed by HRMS. Key 
spectroscopic signals included the amide carbonyl stretch in the IR spectrum at 1634 
cm-1 and in the 1H NMR spectrum the N-H resonance was observed as a multiplet 
ranging from 6.93 to 6.96 ppm.
This synthesis route provided ThrCer in 10 steps from commercially available 
material. The material was supplied to our collaborators (Prof. V. Cerundoloʼs 
research group  at Oxford University) to use in immunological assays. Importantly for 
us, the synthesis gave us invaluable experience with coupling amine 47 with the acid 
chloride of cerotic acid which we hoped would be directly transferable to synthesis of 
14C-labelled ThrCer.
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3.2. Synthesis Of 14C-Labelled Threitol Ceramide.
We next turned our attention to a radiolabelled analogue of ThrCer 39. Mindful of the 
need to minimise any manipulations involving radioactive compounds, we chose to 
incorporate a 14C label into the fatty acid, which would be introduced at a late stage in 
the synthesis. Moreover, in our synthesis of non-radiolabelled ThrCer 39 [Scheme 
16], we had already shown that the acylation of amine 47 could be performed in 
excellent yield even on the small scales that we would be employing in the synthesis 
of its radiolabelled analogue. Na14CN was identified as a convenient source of 14C; 
thus, we envisaged nucleophilic displacement of a suitable alkyl halide would provide 
a straightforward method for generating an alkyl nitrile and hence the carboxylic acid 
upon hydrolysis.
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The required C25-chain alkyl halide 61 was assembled by coupling undecynol 57 with 
alkyl bromide 58 [Scheme 17]. Use of two equivalents of base to deprotonate both 
the alcohol and terminal alkyne in 57, and HMPA as the solvent in the nucleophilic 
substitution, allowed the reaction to proceed without protection of the primary  alcohol. 
The product 59 was confirmed by HRMS and in the 13C NMR spectrum the two 
quaternary resonances corresponding to the internal alkyne were observed at 80.2 
and 80.3 ppm. Subsequent hydrogenation of the alkyne in the substitution product 59 
provided alcohol 60, which was transformed into bromide 61 by treatment with CBr4/
PPh3. One-carbon homologation proceeded efficiently  on heating a solution of 
bromide 61 with Na14CN in DMSO at 85 °C to provide nitrile 62. Finally, base-
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Scheme 17. Synthesis of 14C-labelled ThrCer. (A) TLC of 39 and [14C]-39 develo-
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mediated hydrolysis of nitrile provided 14C-labelled acid 63 in quantitative yield 
[Scheme 17].[71] Following our established procedure for acylation, acid 63 was 
converted into the corresponding acid chloride, by treatment with oxalyl chloride, and 
then reacted with amine 47 to provide Thr[14C]Cer [14C]-39 [Scheme 17]. All 
radioactive products were characterised by TLC analysis against non-radiolabelled 
products that were prepared separately and had been previously  characterised, and 
by taking TLC radiograms of the TLC plates [Scheme 17].
Our approach to the synthesis of Thr[14C]Cer proved to be a very efficient process 
that required minimal radiolabel manipulation. We have also shown that radiogram 
analysis of TLCs of both, fully characterised non-radiolabelled and newly synthesised 
radiolabelled compounds, can be used effectively to monitor reactions involving 
radioactive compounds with minimal health risk. In this manner, we have synthesised 
18 mg of [14C]-39.
Our collaborators, Prof. V. Cerundolo and co-workers at Oxford University, have used 
the radio-labelled ThrCer, [14C]-39, to establish a direct correlation between the 
amount of IFNγ secreted by iNKT cells and the lipid uptake of professional antigen 
presenting cells DCs [Figure 12]. IFNγ ELISA was performed on the supernatant 
taken from 100,000 [14C]-39 pulsed DCs cultured overnight with 50,000 iNKT cells. 
Counts per minutes, cpm, were measured for 500,000 DCs pulsed with varying 
concentrations of [14C]-39 for 36 hours [Figure 12].
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Comparison of IFN-g assay and lipid uptake of DCs pulsed with 14C 
Threitol ceramide. NKT cell IFN-! response to 14C threitol ceramide pulsed DCs 
(indicated by solid line) is consistent with the decrease in lipid uptake measured 
by beta scintillant counting (indicated by dashed line) as cells are pulsed with 
decreasing concentration of 14C threitol ceramide. IFN-! ELISA performed on 
supernatant taken from 100,000 threitol ceramide pulsed DCs cultured overnight 
with 50,000NKT cells. Cpm measured for 500,000DCs pulsed with varying 
concentrations of 14C threitol ceramide for 36 hours. 
Figure 12. Comparison of IFNγ assay and lipid uptake of DCs pulsed with [14C]-39.
3.3. Synthesis Of Biotin-Labelled Threitol Ceramide.
The label of choice in this instance was biotin [Figure 13]. Streptavidin is a tetrameric 
protein of 5.3 kDa which has very high affinity for biotin in aqueous systems, the 
affinity  constant is estimated to be Ka ~ 1015 M-1.[72-74] The protein is capable of 
binding one biotin ligand per monomer. Streptavidin-biotin complexes, where 
streptavidin has been labelled with a fluorescent tag, are easily  detectable; however, 
the biotin moiety has to be available for binding with streptavidin to function as a label 
and this requires that biotin is attached via a spacer.
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The fucosylation process by which fucose is incorporated into glycoproteins on the 
surface of neurones is suspected to play an important role in learning and memory 
processes in the brain. The bioconjugate 64 was used as chemical probe for imaging 
hippocampal neurones in vitro and in vivo which demonstrated the presence of Fuc-
α(1-2)Gal lectins in neurones and neurites [Figure 14].[75] In this example the biotin 
moiety was linked to the disaccharide with a diethylene spacer. Spacing the biotin 
from the disaccharide can help the recognition of the biotin by streptavidin and the 
recognition of the disaccharide by the lectin receptors.
Biotin tags are also used to allow rapid purification of selective species from complex 
mixtures by  biotin-streptavidin affinity chromatography. For example, to study O-
GluNAc-modified glycoproteins and their functional roles, an in situ chemoselective 
biotinylation was developed to facilitate the isolation and purification of the modified 
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Figure 14. Fuc-α(1-2)Gal biotin bioconjugate.
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proteins in tissue samples. Tai et al. effected an enzymatic modification to 65 with a 
galactose transferase mutant that was known to tolerate modification at C2 of 
galactose [Scheme 18]. The crude mixture of 66 and other glycoproteins were then 
treated with an excess of the highly nucleophilic biotin derivative 67 which reacted 
chemoselectively with the ketone 66. The resulting bioconjugate 68 was then purified 
by biotin-streptavidin affinity chromatography [Scheme 18].
αGalCer has also been labelled with biotin utilising the primary alcohol on the 
galactose moiety  which was identified as a suitable position for elaboration [Figure 
15].[76] Zhou and co-workers demonstrated that this position tolerates the introduction 
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Scheme 18. In situ determination by biotinylation of N-acetylglucosamine glycoproteins.
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of small molecules including biotin and other fluorescent probes having only a small 
detrimental impact on the activity of the resulting bioconjugate. Although the 
discovery that 69 activates iNKT cells constituted an important finding, this 
information is not useful for us since we have already deleted this position in the 
sugar head group of our new glycolipid, ThrCer, which leaves just three alcohols for 
interacting with the TCR. We thought that if we attach the biotin label from one of 
these alcohols in a similar manner as Zhou et al., we would likely disturb the 
interactions with the TCR and risk changing the nature of the biological response in 
comparison to that of the parent compound, ThrCer 39.
The challenge for us was to identify a site in ThrCer from which the biotin moiety 
could be attached that would allow its recognition by streptavidin after the CD1d/
ThrCer binding event. At the same time, it would also be critical for the labelled 
ThrCer derivative to retain an activity that resembles that of ThrCer. The location of 
the label would therefore be crucial for the success of this project. From a synthetic 
point of view we thought that late-stage installation of the label would be beneficial. 
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Figure 15. αGalCer biotin bioconjugate.
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This strategy would allow us to diversify this part of the molecule which might need 
tuning, i.e. type of linkage, length of the linkage, different label. With this in mind we 
wanted to evaluate the possibility  of installing the label on the acyl chain, although at 
the outset we did not know how this would impact on the biological activity of the 
labelled glycolipid compound.
It is synthetically convenient to introduce modifications that take advantage of 
existing substituents. For example, the functionalisation of alcohols, or amines, can 
be achieved relatively easy; moreover, these modifications do not often introduce 
new stereocentres which can add to the complexity of the analogues. In comparison, 
modifications that introduce new functionality or substituents are often harder targets 
to synthesise. If a new stereocentre is formed with the modification, then it is also 
important to consider a stereoselective synthetic approach that can give access to all 
the stereoisomers. Although such an approach can be more synthetically demanding, 
it would allow us to evaluate the stereoisomers separately  in biological assays and to 
compare their biological activity.
With these factors in mind, we focused our attention on introducing an additional 
substituent which we could then elaborate and link through to the label. It was 
identified in the X-ray crystal structure of the CD1d-αGalCer complex that at least 
one of the alcohols in the phytosphingosine base is involved in H-bonding with CD1d 
and TCR residues.[29] Mindful that H-bonds between CD1d and ThrCer are important 
elements that hold together the quaternary structure of the protein-ligand complex, 
which is likely to be important for its recognition by the TCR, we turned our attention 
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to the acyl chain. In the X-ray crystal structure of the CD1d-αGalCer complex,[29] we 
observed that the α and β carbons in the acyl chain are not buried in the hydrophobic 
pocket [Figure 16]. This led us to postulate that we might be able to install the label at 
one of these positions and will not affect the CD1d/lipid binding event or the 
recognition of the CD1d-lipid complex by the TCR as these positions are relatively 
distant from the alcohols that are believed to be responsible for activation (assuming 
ThrCer behaves analogously  to αGalCer). Also, aided by  a hydrophilic spacer, a label 
linked from one of these positions should extend away from the complex and be 
available for recognition by streptavidin [Figure 16].
  
Figure 16. (A) Cartoon representation of X-ray crystal structure of CD1d-αGalCer complex. (B) 
Space-filled close up  of X-ray crystal structure of CD1d-αGalCer complex showing sphingosine 
base burial pocket.
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The nature of the substitution that we might introduce needed careful consideration. 
An α-hydroxyl function would offer two common possibilities for elaboration, via an 
ester or an ether linkage. The ester, while relatively easy to make, is not always 
stable in biological assays as it can be easily  hydrolysed by the action of esterases. 
An ether, on the other hand, is far less labile and usually survives biological assays in 
vitro and in vivo; however, it represents a more challenging bond to make at such a 
late stage in the synthesis. Ether syntheses usually require the preparation of an 
alkoxide at one of the reactive partners, and a good leaving group in the other 
reactive partner. While the hope in an ether synthesis is that the alkoxide behaves as 
a nucleophile and displaces the leaving group  in the electrophile, it can also behave 
as base or react with a different electrophilic centres elsewhere in the molecule.
We turned our attention to introducing an α-azido function next to the amide in 
ThrCer as this would open up a range of possible attachment strategies. An azide 
offers the possibility  to elaborate further as a substituted amine, or through another 
amide bond, after reduction of the azide to the primary amine. Amines are usually 
very  stable in biological assays; they are also good nucleophiles and as bases, are 
readily protonated in weakly acidic media.†  Amines often participate in H-bonding 
interactions with the protein; they are good H-bonding donors and acceptors‡  and 
their interactions with CD1d residues might affect the quaternary structure of CD1d 
which could have implications on the factors that determine the immune response. 
More significantly, under physiological conditions an amine would be protonated, and 
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† Typical pKas for protonated amines range between 10 and 12 units.
‡ Tertiary amines cannot participate in H-bonding as H-donors but they are good H-acceptors.
it would introduce undesirable charge in the vicinity of this hydrophobic site. For 
these reasons we discounted the possibility of using an amine in the linker. On the 
other hand, amide bonds are found commonly in biological systems and are less 
susceptible to non-enzymatic hydrolysis than esters. Amide bonds are also relatively 
easy to make and this fitted well with our strategy which leaves this bond synthesis 
for a late stage elaboration [Scheme 19' and 19'']. The azido functionality will provide 
orthogonal protection for the amide bond coupling with amine 72. More importantly, 
the azido intermediate 70 can be used directly in azide-alkyne [3+2] cycloaddition 
reactions to provide a 1,2,3-triazole [Scheme 19' and 19'']. We, therefore, focused on 
the synthesis of this key intermediate 70; the retrosynthesis is outlined below 
[Scheme 19' and 19''].
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Scheme 19'. Retrosynthetic analysis of key intermediate azide 70.
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We have already described the synthesis of the azide 48 starting from 
phytosphingosine and 2,3-O-benzylidene-protected threitol [Scheme 15]. This time 
though, we focused first on the azide reduction in 48 rather than deprotecting the 
alcohols. Hydrogenation of alkyl azides to alkyl amines is a common and very 
effective method to achieve this deprotection and the crude product usually requires 
minimal purification; however, the reduction conditions are likely to induce 
hydrogenolysis of the benzylidene acetal as well, and wary of the solubility problems 
that are associated with amphiphilic lipids, we turned to another more selective 
method. The Staudinger reaction is another common method for reducing an azide to 
an amine. In this reaction, a phosphine, usually Ph3P, reacts with the azide function 
to form an imino phosphorane with the liberation of nitrogen gas. The imino 
phosphorane can be broken down with water, freeing the amine and producing a 
phosphine oxide as a by-product. Although there are examples in the literature where 
the imino phosphorane is stable at room temperature in aqueous media, in which 
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Scheme 19''. Retrosynthetic analysis of key intermediate azide 70.
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case refluxing conditions are required to successfully free the amine, the reaction 
conditions are nevertheless very mild, i.e. chemoselective for the azide, and usually 
produce the amine in yields in excess of 90%.
However, the purification of the amine product can be problematic and separating it 
from the phosphine oxide by-product can be time-consuming and compromise the 
yield of the reaction. Trimethylphosphine has also been shown to efficiently reduce 
azides to amines.[64] This small trialkyl phosphine has the disadvantage that it is 
easily  oxidised by air; triphenylphosphine, on the contrary, is very stable under 
aerobic conditions; however, trimethylphosphine oxide is a solid with a high vapour 
pressure and can be removed from the product mixture under reduced pressure.[77] 
The reduction of 48 with trimethylphosphine yielded the requisite amine 72, which 
was used in the next step without purification [Scheme 20].
We needed to synthesise the α-azido acid 73 for our next coupling reaction [Scheme 
19' and 19'']. The Strecker reaction is a method in which an aldehyde is reacted with 
HCN§  in an aqueous ammonium hydroxide solution and yields an α-amino nitrile 
product which can be hydrolysed to the corresponding α-amino carboxylic acid. This 
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Scheme 20. Staudinger reduction of azide 48 provided amine 72.
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§ HCN is generated in situ by the reaction of NaCN and NH4Cl.
important reaction has received considerable attention over the years. Strecker-like 
reactions with imines continue to being developed and in this field we find catalytic 
and stereoselective processes for the synthesis of α-amino nitriles; which, after nitrile 
hydrolysis, we can potentially convert into the desired α-azido carboxylic acid by  an 
azido transfer reaction in a similar manner to that described for the synthesis of 52. 
However, this approach to our α-azido acid target requires several additional steps 
and add a considerable amount of labour and expense to the synthesis.
Although we considered preparing the desired α-azido carboxylic acid in an 
enantioselective fashion, it was more convenient in the first instance, to synthesise α-
azido acid as a racemate although this consequently means that the target product 
will be obtained as a mixture of diastereoisomers. Moreover, we have no way  of 
knowing in advance how the biology of these two target diastereoisomers will differ 
from each other. After a discussion with our collaborators, we agreed to provide the 
target biotin-labelled compound as a mixture of diastereoisomers in the first instance. 
Taking this into account and mindful of the tendency of cerotic acid derivatives to 
present us with solubility  problems, we turned our attention to the Hell-Volhard-
Zelinsky reaction [Scheme 21].[78-80]
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Studies into the mechanism of this reaction suggest that the reaction proceeds via 
the haloenol which reacts with a bromonium ion source in the reaction mixture;[81, 82] 
the most common source of bromonium ion is Br2 but NBS can also be employed. 
The resulting α-bromo acid bromide can then be converted into the corresponding α-
bromo carboxylic acid by hydrolysis of the intermediate acid bromide.
The Hell-Volhard-Zelinsky procedure gave us the requisite α-bromo cerotic acid 74 
[Scheme 22].[83, 84] The product was recrystallised from hexanes and used without 
further purification in the following step. With this compound in hand, our attention 
turned to the displacement reaction. We found a few examples of α-bromo carbonyl 
displacement reactions by an azido nucleophile although no examples where this 
carbonyl is a free carboxylic acid. We were aware that we could convert the 
carboxylic acid to the corresponding methyl ester and effect the α-bromo 
displacement in line with previous literature work but we were more interested in 
exploring the possibility  of performing the displacement on the free carboxylic acid. 
We had in mind to minimise the need for aqueous work-up and silica column 
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Scheme 21. Proposed mechanism for the Hell-Volhard-Zelinsky reaction.
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purification because in our experience of working with this class of long chain fatty 
acids, an aqueous work-up  complicates the extraction and purification steps due to 
very low solubility of the products and their tendency to form emulsions.
We thought that to succeed in displacing the α-bromide without protecting the 
carboxylic acid we needed to compare the nucleophileʼs pKa with that for the 
carboxylic acid. All nucleophiles can behave as bases and our fears were that if the 
free carboxylic acid is deprotonated under the reaction conditions by the nucleophile, 
it will not only render the nucleophile less nucleophilic, but the α-bromo carboxylate is 
also a worse electrophile. The pKa of hydrazoic acid has been measured at 4.6 in 
water.[85] The pKa of a carboxylic acid is also around 5 which led us to think that in a 
reaction mixture there might be an acid-base equilibrium of the azide salt and the 
carboxylic acid with hydrazoic acid and the carboxylate from which the reaction might 
proceed. Initially we explored employing NaN3 as a nucleophilic source of azide in 
DMF to displace the bromide. In spite of following literature precedent for this 
transformation[86, 87] the reaction did not proceed to products and only  the starting 
bromide was recovered after heating the reaction mixture to 70 °C  for twelve hours. 
We then considered TMSN3 as the source of nucleophilic azide. As a notable 
advantage, the reaction could be performed in low boiling point solvents such as THF 
or CH2Cl2 and the by-products, as well as the excess of the reagent, are also likely to 
be volatile for easier work-up.
The reaction of TMSN3 with α-bromo cerotic acid in THF did not yield products at r.t. 
nor at 70 °C, even when an excess of reagent was employed and the mixture was 
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stirred for a week at 70 °C. The reaction was monitored by mass spectrometric 
analysis of the crude mixture. We postulated that the reaction needed activation of 
the TMSN3. Cesium fluoride can act as a fluoride source and in combination with 
TMSN3 would catalyse the bromide displacement.[88, 89] The fluoride anion has a high 
affinity  silicon forming one of the strongest covalent single bonds known;[90] the Si-F 
bond energy averages at 582 kJ mol-1. We were pleased to see the formation of the 
desired product 73 when one equivalent of CsF was employed in the reaction but 
even after three days and with an excess of CsF, the reaction did not go to 
completion. As the product 73 and starting bromide were inseparable on silica, we 
chose to develop  the reaction further to ensure complete consumption of starting 
material which would facilitate purification.
We thought that the low solubility of the CsF salt in THF was the cause of our 
problems. HF, another mild source of fluoride, can also be employed for targeting silyl 
groups, which in this case would encourage the formation of HN3 in situ that we 
hoped would act as a mild source of nucleophilic azide. Using the Py.xHF complex in 
place of CsF over twelve hours in THF at 45 °C, we now saw complete conversion of 
the starting material to the desired azide product 73 when 1.5 of equivalents Py.xHF 
(70 wt. % in pyridine) were employed as the promoter [Scheme 22]. This was a 
satisfying result because no aqueous work up  was required and the product was 
isolated by simple evaporation of the volatiles. Electrospray mass spectral analysis 
showed only  one peak corresponding to the product and TLC analysis showed only 
traces of impurities. This material was used in the next step without further 
purification.
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We were encouraged by this result and with the α-azido carboxylic acid in hand we 
focused on the coupling reaction ahead. Activation of the carboxylic acid 73 was 
achieved in situ with EDC, and reaction proceeded with excellent chemoselectivity for 
the amine over the alcohols, providing amide 71 as a 1:1:1:1 mixture of four 
diastereoisomers [Scheme 23]. The global deprotection of the acetal and ketal in 71 
was achieved in one step employing 60% Ce(OTf)3 as Lewis acid and provided our 
target 70 as a 1:1 mixture of two diastereoisomers [Scheme 23].
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Scheme 23. Synthesis of key azido intermediate 70.
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At this stage we had successfully synthesised key azido-intermediate 70. In our 
retrosynthetic analysis of 70 we discussed the possibilities that an α-azido 
substituent offers for further elaboration. We chose to proceed, in the first instance, 
with the [2+3] copper-catalysed cycloaddition of the azide 70 with a terminal alkyne to 
incorporate the label.
1,2,3-Triazole derivatives have been used successfully in biotinylation reactions. For 
example, in a high-throughput study of protein-membrane interactions Losey et al. 
coupled the diacylglycerol azide derivative 76 with bPiotin alkyne derivative 75 in the 
presence of catalytic amount of CuI to yield the biotin conjugate 77 in moderate yield 
[Scheme 24].[91] Under these conditions and in an organic solvent like THF, the Cu(I)-
catalysed alkyne-azide cycloaddition required an amine base like Hünigʼs base to 
deprotonate the alkyne after complexation with the Cu(I) ion to facilitate the formation 
of the Cu-acetylide which has been shown to be the first step of the catalytic cycle.[92]
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Scheme 24. [3+2] Cycloaddition biotinylation using CuI as catalyst.
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In another example, the biotin alkyne derivative 79 was coupled with a fully 
deprotected N-acetyl-D-glucosamine azide derivative 78 that afforded the 
glycoconjugate 80 [Scheme 25].[93] The reaction conditions employed sodium 
ascorbate as reductant for reducing Cu(II) to Cu(I) in situ and tris(triazolyl)amine as a 
ligand for copper. These conditions are advantageous in that the prone-to-oxidation 
Cu(I) ions required in the reaction are generated in situ in small amounts and that it 
was observed that this ligand accelerated the reaction.[94]
In a modelling study of chemical programming of monoclonal aldolase antibody, the 
β-lactam 81 was conjugated to the biotin moiety  82 by  click chemistry ligation 
employing copper wire as catalyst in acetonitrile [Scheme 26].[95] In this process the 
copper metal is oxidised to Cu(I) by oxygen (perhaps the CuSO4 can also behave as 
an oxidant getting reduced to Cu(I) to a small extent).[96, 97]
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Scheme 25. CuII salts can be employed as pre-catalysts.
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This strategy is attractive, not only because of the shorter synthesis, but also 
because it is more convergent which has the potential for a higher yielding synthesis. 
Polyethylene glycol, PEG, linkers are commercially available in different lengths and 
are biocompatible. They  are also soluble in a range of solvents including water. A 
PEG spacer should improve the hydrophilicity of the label making it available for 
recognition in aqueous assays. With the position to attach the label identified we 
developed a retrosynthetic strategy  for assembling the labelled ThrCer target 84 
[Scheme 27].
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Scheme 26. Copper metal can also serve as pre-catalyst.
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The biotin moiety is normally linked to a substrate by way of an amide bond, taking 
advantage of the carboxylic acid already present in the molecule; however, cleavage 
of this amide bond by the endogenous enzyme biotinidase can be a problem in 
biological and whole-cell assays. Structural modifications of biotin can enhance the 
stability of this amide bond, but these often result in a decrease in streptavidin 
O O O
O
S
NHHN
O
HH
N
23 H
N
O
O
OH
OH
13HO
OH
OH NH
O O O
O
S
NHHN
O
H
H
N3
H
N
O
O
OH
OH
OH
OH NH
HO
S
NHHN
O
H
H
O
HOO O O NH2
FG
HO O O OH
NN
23
13
triethylene glycol
D-(+)-Biotin
70
84
85
86
Scheme 27. Retrosynthetic analysis of biotin-ThrCer 84.
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affinity. A  compromise between stability  and affinity  is generally reached by 
introducing a small (but larger than methyl, for example ethyl) α-amide substituent.[98] 
We decided not to make any of these modifications to the biotinamide moiety as this 
topic is still being developed in the literature and we wanted to take full advantage of 
the biotinamide-streptavidin complex having one of the largest non-covalent affinities 
known in water (Ka ~ 2.5 1015 M-1), which would maximise the chances of the label 
being detected while bound to our ThrCer substrate.
We started the synthesis of the alkyne 85 by mono-alkylating triethylene glycol 
[Scheme 28]. Alkyne 87 was prepared employing one equivalent of nBuLi in THF at 0 
°C  for one hour to provide the corresponding lithium alkoxide followed by  dropwise 
addition of propargyl bromide at this temperature. After work up, the desired alkyne 
product was obtained in 25% yield. A small amount of dialkylated product was also 
formed. Although the starting material was conveniently  washed away in the aqueous 
phase, TLC analysis indicated that a considerable amount of unreacted starting 
material accounted for the remaining mass balance. The alkoxide was also prepared 
using NaH (in DMF and in THF) and, KH (in THF); however, the method employing 
the lithium alkoxide afforded the best yields [Scheme 28].
Azidation of 87 was achieved in good yield by converting the alcohol into a leaving 
group in situ with bis(p-nitrophenyl)-phosphoryl azide, BNPPA. which was readily 
prepared by nitration of commercially available diphenylphosphoryl azide, DPPA. The 
reagent DPPA can be used in combination with DBU for the conversion of allylic 
alcohols into allylic azides.[99] However, this phosphoryl reagent is not sufficiently 
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electrophilic to react in the same way with simple alkyl alcohols. Fortunately it has 
been demonstrated that nitration of DPPA affords BNPPA, which smoothly  reacts with 
alkyl alcohols to provide the corresponding alkyl azide in one step.[100] Undoubtedly  it 
is the presence of the two powerful electron-withdrawing nitro groups, which 
increases considerably the electrophilicity of this phosphoryl azide. In the preparation 
of BNPPA, the product can be isolated from the reaction mixture by simple 
recrystallisation and can be stored (-20 °C) which make this reagent amenable to 
use.
A mixture of 1.1 equivalents of BNPPA and the alcohol substrate 87 in toluene was 
treated at 0 °C with 1.1 equivalents of DBU and rapidly  stirred for twelve hours 
[Scheme 28]. After this time, TLC  analysis showed that the reaction was complete as 
evidenced by the disappearance of the starting alcohol and the formation of a higher 
running new spot. The work-up proved to be highly problematic as p-nitrophenoxide 
appeared to be generated from the by-product salt. Several base washes with a 
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Scheme 28. Synthesis of the requisite amine 86.
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saturated solution of NaHCO3 failed to separate the phenol from the organic extracts. 
A portion of the solution was also washed with Na2CO3 solution, which appeared to 
wash away all of the p-nitrophenol in the first instance, but when the organic phase 
was concentrated, more coloured material was generated, implying the continued 
presence of p-nitrophenol. In spite of this, the organic fraction was concentrated 
under reduced pressure and the residue was submitted to column chromatography 
affording the desired azide 88, which was still contaminated with approximately 5% of 
p-nitrophenol. Azide 88 was reduced to the corresponding amine with 
trimethylphosphine in THF. After complete consumption of the starting material, the 
volatiles were evaporated under high vacuum. The crude amine 86 was washed with 
1.0 M HCl solution and the resulting ammonium salt was then back-extracted with 
CH2Cl2 after neutralising the aqueous phase with a 2.0 M NaOH solution.
In the following step  we coupled D-(+)-biotin with amine 86 [Scheme 29]. D-(+)-Biotin 
is insoluble in most organic solvents, which complicated this step. Carbodiimide 
activation of biotin is generally  performed at high temperature to overcome the poor 
solubility of the carboxylic acid and these methods usually  employ nucleophilic 
catalysts, such as N-hydroxybenzotriazole, HOBt, which is commonly used in peptide 
coupling reactions. We wanted to steer away from these methods, wary that our 
amide product would be soluble in water and difficult to extract from the aqueous 
phase in the work-up step. It is possible to obtain commercially the N-
hydroxysuccinimide, NHS, biotin ester, which reacts readily  with amines to afford the 
corresponding biotin amides in high yields; however, this activated ester is relatively 
expensive. Another activated ester capable of reacting with amines is the 
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pentafluorophenyl ester, PFP,[101, 102] which is readily prepared in situ from the free 
carboxylic acid and we elected to investigate this reagent for our amidation.[103]
Pentafluorophenol trifluoroacetate was synthesised in one step by treatment of 
pentafluorophenol with TFAA in the absence of solvent at r.t. for twelve hours and 
then purified by distillation. D-(+)-Biotin was then suspended in DMF (0.1 M) and 
treated with three equivalents of Et3N at 0 °C  and stirred at this temperature until the 
solution became clear (20 minutes). After this time, one equivalent of 
pentafluorophenol trifluoroacetate was added dropwise at 0 °C. The mixture turned 
pink. The resulting solution was stirred for four hours after which time a white solid 
had precipitated and TLC showed a complete consumption of the starting acid and 
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Scheme 29. Synthesis of the requisite alkyne 85.
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the formation of ester 89 [Scheme 29]. The amine 86 was added at this point as a 
solution in DMF at 0 °C. TLC  analysis showed that the reaction proceeded rapidly. 
After four hours the DMF and pentafluorophenol were evaporated under reduced 
pressure. The residue was purified by column chromatography (CHCl3 / MeOH, 9:1) 
to afford 70% of the desired product plus 20% of the biotin pentafluorophenyl ester 
[Scheme 29]. At this stage we had both requisite fragments for the key click 
chemistry coupling reaction.
The azide-alkyne [3+2] cycloaddition reaction was first studied by Huisgen in the 
1980s under thermal conditions, along with other 1,3-cycloaddition reactions.[104] 
Under thermal conditions, the alkyl azide only reacts with electron-deficient alkynes, 
and only at elevated temperature; moreover, the products are generally  produced as 
a 1:1 mixture of regioisomers [Scheme 30].
In the 1990s, various efforts to control the regioselectivity were published that 
widened the scope of this reaction;[105-107] however, it was not until 2002 that a 
reliable, mild and regioselective method was found. This was described, in two 
almost simultaneous reports by Torn∅e et al.[108] and Rostovtsev et al.[109] These 
groups showed that Cu(I) ions effectively catalyse the 1,3-dipolar-cycloaddition. 
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Scheme 30. Azide-alkyne [3+2] cycloaddition under thermal conditions.
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Under these new conditions the reaction constitutes the best example of click 
chemistry: it affords very high yields of product, the process is compatible with a wide 
range of solvents including water, it is a highly regioselective and thermodynamically 
favoured process driven by the formation of an aromatic compound [Scheme 31].
Synthetically, the Cu(I)-catalysed azide-alkyne “click” is operationally  simple and 
yields a single regioisomer which not only simplifies the characterisation and 
purification steps but also means that it is simpler to interpret the biological results 
from assays involving a single regioisomer than from assays with a mixture of 
regioisomers. In this light, we proceeded with a variant of the Cu(I)-catalysed azide-
alkyne “click” in which the Cu(I) ions are generated in situ from Cu(II) by the action of 
sodium ascorbate [Scheme 32].[110]
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Scheme 31. Proposed mechanism for the azide-alkyne [3+2] cycloaddition catalysed by Cu(I).
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The reaction was performed at 40 °C to maintain the mixture of starting materials and 
reagents in solution. TLC analysis showed complete consumption of the starting 
alkyne 85 and azide 70 after twelve hours. The triazole product 84 was precipitated 
from the reaction mixture by adding water at r.t., and then purified by silica gel 
column chromatography. We were delighted to have come to the end of a synthesis 
that afforded 11 mg the of biotin-labelled ThrCer 84 [Scheme 32].
The biotinylated ThrCer was tested by MD Vincenzo Cerundolo et al. at Oxford 
University  for its ability  to stimulate the secretion of IFNγ and the results were 
compared with the parent compound. Figure 17 shows that 84 is capable of inducing 
an immune response that it is similar in magnitude to that of ThrCer confirming our 
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original hypothesis that incorporating the biotin label with a PEG linked to the fatty 
acid chain would not affect the bioactivity of the glycolipid.
Cerundolo et al. also tested for the ability  of CD1d to load and externalise the 
labelled ThrCer 84. Figure 18 shows staining of antigen presenting cells, APCs, with 
a biotin-specific reagent–fluorescent streptavidin, fluorescent biotin antibody and with 
fluorescent soluble iNKT TCR–on the cell surface confirming that 84 is being 
externalised for presentation. Panel c) demonstrates that the modified lipid 84 is 
recognised by iNTK cell TCRs. Panel d) shows a double staining with biotin antibody 
and with soluble iNKT TCRs demonstrating that the increase in fluorescence is linear 
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and lipid concentration dependent, suggesting that the soluble iNKT TCRs recognise 
84 as well as the biotin antibody recognises the biotin label.
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IV. TOWARDS THE SYNTHESIS OF α-GALACTOSYL DIACYLGLYCEROL
4.1. Naturally Occurring CD1d Agonists.
Several CD1d agonists have been discovered,[111] and to date, the most studied of 
these is αGalCer.[112] However, αGalCer is neither an endogenous nor an exogenous 
lipid; αGalCer has not been found to be a lipid component of any of the pathogens 
studied. Thus in search of the natural antigen for CD1d, attention has turned to other 
glycolipids of mammalian and pathogenic origins.[113, 114] One such glycolipid is 
isoglobotrihexosylceramide 90, iGb3, which was postulated by Mattner et al. to be 
the natural endogenous antigen for CD1d and responsible for the survival of iNKT 
cells in the thymus in mice [Figure 19].[115, 116] iGb3 is a trisaccharide ceramide lipid 
that features a 26 carbon-atom acyl chain, in analogy with that found in αGalCer. The 
glucose reducing sugar of this trisaccharide, is glycosylated through a β glycosidic 
bond to the ceramide base, which is in contrast with the galactose moiety  of αGalCer 
which presents an α glycosidic linkage to the ceramide base [Figure 19].
However, the conclusion that iGb3 is solely  responsible for the selection of iNKT 
cellls has been contested by Speak et al.[117] They showed that the experiments 
leading to the proposal of the principal role for iGb3 being the natural antigen for 
CD1d could have led to a condition called lysosomal storage disease in which 
glycolipids are not processed as efficiently as normal in the lysosome. Speak et al. 
claimed that it was lysosomal storage, and not the absence of iGb3, that caused 
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iNKT cells not to be selected for survival, from which the principal role of iGb3 was 
originally inferred.[115] The contestants argued that lipid accumulation in the lysosome 
causes non-specific lipid loading into the hydrophobic pockets of CD1d, which 
diminishes the chances for an unidentified natural ligand successfully  binding with 
CD1d. However, there are no questions over the fact that iGb3 is an agonist of CD1d 
and an unidentified role for this glycolipid in CD1d-mediated activation of iNKT cells 
cannot be ruled out.
α-Galacturonic acid ceramide 91 and β -glucuronic acid ceramide 92 are glycolipids 
that have also been found to activate iNKT cells [Figure 20]. These glycolipids have 
been isolated from Sphingomonas and constitute the first direct evidence that 
glycolipids isolated from pathogenic bacteria bind to CD1d and are recognised by 
iNKT cell TCRs resulting in an immune response against the invader.[30, 118]
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In another study, non-sphingolipids were isolated from Borrelia burgdorferi, the 
causal agent of Lyme disease, and it was demonstrated that these agents were also 
agonists of CD1d.[52] These glycolipids are composed of a galactose polar head 
group that is α-glycosylated to a diacyl-syn-glycerol moiety [Figure 21]. In their study, 
Kinjo et al. identified a range of acyl chains on the glycerol fragment but it was not 
possible to distinguish their exact location i.e. which acyl chain was on which alcohol. 
Thus, they synthesised a range of these glycolipids featuring a combination of the 
acyl chains from the repertoire that had been found in the wild.
The results very nicely demonstrated the intricate relationship  between the activity of 
the antigen and its structure. For example, compound BbGL-IIc and BbGL-IIf are 
acylated with different fatty acids: BbGL-IIc features an oleic acid on syn-1 glycerol 
and a palmitic acid on syn-2, while BbGL-IIf features a linoleic acid on syn-1 glycerol 
and an oleic acid on syn-2 [Figure 21]. These two α-galactosyl diacylglycerol 
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Figure 20. Glycoceramides from pathogenic origin are agonists of iNKT cells.
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derivatives exhibit very different biological activity. BbGL-IIc performed as an antigen 
for CD1d and was the best of those compounds tested with mouse iNKT cells, 
although interestingly this glycolipid failed to induce high levels of cytokine secretion 
when it was tested with human iNKT cells. In sharp  contrast, BbGL-IIf, which did not 
activate mouse iNKT cells, induced the highest production of cytokines of those 
compounds tested when evaluated with human iNKT cells. In addition, when the 
compounds were very similar structurally the activity was similar too; one example is 
the regioisomers BbGL-IId and BbGL-IIf, which both underperformed in mouse 
iNKT cells while in assays with human iNKT cells they both induced the production of 
large amounts of cytokines. These results are a cautious reminder that mouse 
models are not always useful for predicting the bioactivity of structurally similar 
analogues in humans.
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Our research group has established a collaborative project with Prof. Michael 
Brennerʼs research group  at Harvard University Hospital to investigate further the role 
of these glycolipids in CD1d-mediated immunity and to consider analogues with non-
natural acyl substitution on the glycerol fragment for the discovery of new bioactivity. 
We therefore wanted to develop a general and flexible synthesis of αGalDAG.
4.2. 1,2-Cis-Stereoselective Glycosylation Reactions.
In our retrosynthetic analysis of αGalDAG we chose to install the fatty acids at a late 
stage of the synthesis [Scheme 33]. This is a good strategy that would allow us to 
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Figure 21. Examples of αGalDAG agonists of iNKT cells.
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introduce diversity  into this part of the molecule from a common precursor. It also 
allows us to consider a range of protected sugar donors for the key glycosylation step 
which might be important to maximise the α-stereoselectivity in this reaction.
We considered a range of protecting groups for our galactosyl donor. For example, 
employing acetate-protected sugar donors was dismissed, as the chemoselective 
removal of acetates in the presence of other acyl groups is difficult. In addition, it 
would be important for the donor not to have an acetate protecting group at C(2), as 
this type of protecting group  can participate in the glycosylation step  directing the 
selectivity β in sugars like glucose and galactose (1,2-trans-diequatorial), and in 
sugars like mannose α(1,2-trans-diaxial) [Scheme 34].
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Benzyl ethers are commonly used electron-rich protecting groups for sugar donors in 
glycosylation reactions. Sugar donors protected with benzyl ethers are sometimes 
called “armed donors” because of their increased reactivity and ease of activation. 
Glycosylation reactions involving armed donors usually proceed under mild 
conditions and often at low temperatures.[119-121] In contrast, sugar donors protected 
with electron-withdrawing groups (these donors are called “disarmed donors”) 
generally  require harsher conditions for activation.[120, 121] Benzyl ether protecting 
groups do not participate in the glycosylation step  and do influence the 
stereochemical outcome of the reaction in the way that esters do.[122, 123]
The benzylidene acetal is another common protecting group for simultaneously 
protecting the C(4)OH and C(6)OH in sugar donors. This versatile protecting group 
attracts attention because it can be removed under both acidic hydrolytic conditions, 
and by hydrogenolysis. It has also attracted attention because it can be reductively 
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opened providing a free C(6)OH or C(4)OH depending on the reducing agent that is 
employed [Scheme 35].[124-128]
Recent studies have shown that the presence of a 4,6-benzylidene acetal affects the 
reactivity of the donor and can also influence the stereochemical outcome of some 
glycosylation reactions.[129-131] The acetal is electron-rich in nature which should 
favour an increase in reactivity of the donor, but it also exerts a torsional effect that 
disfavours the formation of free ions. Crich et al. has studied the influence of this 
acetal protecting group on the stereochemical outcome of several glycosylation 
reactions and has demonstrated that a 4,6-benzylidene acetal can be used as an 
effective 1,2-cis-directing protecting group [Scheme 36].
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We were interested in identifying a galactosyl donor that affords high levels of 1,2-cis-
selectivity and that requires minimal protecting group manipulation steps after the 
glycosylation reaction. Boon et al.[132] reported that donor 94 provides, under 
optimised conditions, very high levels of selectivity in favour of the α-anomer 
[Scheme 37]. The high levels of selectivity were thought to be due to the remote aryl 
ester group  participating in the reaction. This example provides one of the most 
supportive pieces of evidence in the literature for the participation of remote groups in 
glycosylation reactions. The data in this report evidenced a shift in mechanism 
between alkyl ester and aryl ester protecting groups. However, the situation is 
complicated by the high selectivity obtained with the pivalate ester protecting group, 
pointing to steric factors also being important in determining the selectivity of the 
reaction [Scheme 37].
O
O
BnO
BnO
O
O R
i) BSP, TTBP,
Ph
O
O
BnO
BnO
O
SPh
Ph
OO
BnO
OBnO
SPh
Ph
OO
BnO
OBnO
O
Ph
R
OO
BnO
BnO
O
SPh
Ph
OO
BnO
BnO
O
O
Ph
R
Tf2O
Scheme 36. The 4,6-benzylidene protecting group favours 1,2-cis products.
ii) ROH
i) BSP, TTBP,
Tf2O
ii) ROH
i) BSP, TTBP,
Tf2O
ii) ROH
Towards the Synthesis of α-Galactosyl Diacylglycerol
90
In a recent study, Crich and co-workers investigated the role of the remote ester at 
C(4) in governing the high levels of α-stereoselectivity  obtained for this type of donor 
[Scheme 38].[133] They  found that if they quench the promoted donor 94 at low 
temperature using 18O-labelled water, the 18O-label was only incorporated in the 
hemiacetal oxygen, compound 98, and not in the ester, compound 99, as it would be 
expected if 96 is in equilibrium with 97 [Scheme 38]. This study raised questions 
about the origins of the α-stereoselectivity for this donor and while it does not provide 
us with answers, it tells us that the proposal that this remote axial ester can 
participate in a similar fashion as that of an ester at C(2) is unlikely and that perhaps, 
it is a balanced combination of steric and stereoelectronic factors that determine the 
stereochemical outcome for this reaction.[133]
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In another example of 1,2-cis-stereoselective glycosylation, the donor and the 
acceptor are brought together through a tether linking via the C(2)OH of the donor 
and the nucleophilic alcohol of the acceptor [Scheme 39]. This type of pre-assembly 
determines the face to which the acceptor is delivered upon activation of the 
anomeric centre in the donor. In a pioneering example from Bols,[134, 135] the acceptor 
is positioned on the α-face of the donor via a silylene tether. Upon activation of the 
thioglycoside, the silyl ether attacks the electrophilic anomeric centre with complete 
stereoselectivity for the α-face. This approach to 1,2-cis-stereoselective glycosylation 
has been applied to other sugars like mannose with equal success.[136]
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Besides silyl tethers, acetals have also been used to pre-assemble the donor and the 
acceptor and direct the stereoselectivity of subsequent glycosylation reactions. The 
most notable example is the para-methoxybenzylidene acetal [Scheme 40].[137-139] 
Ogawa and co-workers have demonstrated that it is possible to trap the benzylic 
cation resulting from the oxidation of the PMB group with the acceptor alcohol 
positioning the acceptor for 1,2-cis-aglycon delivery. This approach is advantageous 
over the silicon tether in that the PMB group  can be introduced early in the synthesis 
and be carried through other protecting group manipulations, and glycosylation steps, 
until the 1,2-cis-glycosidic bond is required. In contrast, the silylene tether is 
hydrolytically highly unstable and is not amenable to different manipulations.
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It is also possible to achieve high levels of stereo 1,2-cis stereoselectivity in the 
absence of directing protecting groups or pre-assembly of the donor and acceptor. 
Lemieux reported that 2,3,4,6-tetrabenzylgalactosyl bromide reacts in the presence 
of an excess of bromide ions with a series of acceptors with complete α selectivity 
[Scheme 41].[123] Primary  alcohol acceptors afforded 60 to 65% of the α-anomer 
while secondary  alcohols afforded only moderate yields ranging from 40 to 45% of 
the α-anomer. The remaining mass balance was accounted to be hydrolysed and 
unreacted donor. Notably, the β-anomer was not found among the products for this 
reaction.
Scheme 40. Acetal tether facilitates intramolecular aglycon delivery.
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Lemieuxʼs findings can be explained if we consider that under the reaction conditions 
and in the presence of an excess of bromide ions, the α-glycosyl bromide 
equilibrates with a small amount of the more reactive β-anomer, which reacts with the 
acceptor in an SN2 fashion to give the α product [Scheme 42]. This α-halide can also 
dissociate to give α-contact ion pairs and if these react with the acceptor, they will 
also give β-products. If α-contact ion pairs are in equilibrium with free ions the latter 
react rapidly  with the acceptor and also favour the α products. The preference for the 
free ions to afford α-products is a consequence of the anomeric effect that stabilises 
the α-anomer via endo- and exo-orbital overlap while the β-anomer is stabilised only 
by exo-orbital overlap. This higher thermodynamic stability of the α-anomer over the 
β- implies that the transition state leading to the formation of the β-anomer is higher 
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in energy than that of the transition state leading to the formation of the α-anomer. 
Consequently, the α-anomer will form faster from free ions than would the β-anomer.
The specific mechanistic path of a glycosidation reaction is highly dependent on the 
reaction conditions, the steric and stereoelectronic attributes of the donor and 
acceptor. Letʼs consider an α or β-donor that is activated or promoted under the 
reaction conditions [Scheme 42]. For a glycosyl bromide or glycosyl iodide, this might 
simply be achieved by dissolving the donor and an excess of the halide salt with the 
acceptor. The equilibrium highlighted in red will be quickly established, and favours 
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the more stable species, namely  the α-halide by  virtue of the anomeric effect. 
However, while this activated α-donor is generally  capable of reacting with the 
acceptor in an SN2 fashion, if an equilibrium with a more reactive species is 
established, i.e. β-bromide, the acceptor will react preferentially  with this more 
reactive species and this can lead to high levels of steoreoselectivity.
However, this type of reaction has the drawback of having to prepare a highly 
hydrolytically  unstable donor, i.e. the armed-glycosyl bromide. In a recent publication, 
Shingu et al. showed that armed-hemiacetal benzylated galactose 100 can be 
employed as an alternative sugar donor to provide the glycoside product 101 with 
excellent levels of stereoselectivity in favour of the α-anomer [Scheme 43].[140]
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In this remarkable discovery, the hemiacetal 100 is first converted to the 
corresponding glycosyl bromide. The excess reagent required for carrying out this 
conversion does not interfere detrimentally  with the glycosylation reaction that follows 
in situ. These reaction conditions have the obvious advantage of not requiring to 
isolate the highly unstable perbenzylated galactosyl bromide.
In a separate study, Shingu et al. discovered that this glycosylation also occurs when 
DMF is employed as the solvent in the absence of TMU with similar results as in 
CH2Cl2 in the presence of an excess of TMU.[141] 1H NMR spectra recorded at low 
temperatures of the glycosyl bromide in DMF indicated that an α-glycosyl species 
corresponding to the DMF adduct was the major component [Scheme 44]. The 
authors postulated that in the presence of excess bromide ions the α-glycosyl-TMU 
adduct can form the more reactive β -glycosyl bromide easier than the α-glycosyl 
bromide can, and therefore TMU acts as a facilitator in this glycosylation.
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We have summarised the most prominent examples in the literature of directed 1,2-
cis stereoselective glycosylation reactions and discussed the various factors 
governing their stereochemical outcome. Consequently, we selected the benzylated 
galactosyl bromide for our glycosylation with the 1,2-isopropylidene glycerol based 
on the rationale that this hydrolytically unstable donor can be prepared in situ and 
that the glycosylation affords high levels of selectivity in favour of the desired 1,2-cis-
product. The benzyl protecting group can be conveniently removed by 
hydrogenolysis after the glycosylation step  and the alcohols can be re-protected with 
a protecting group  that is orthogonal with the acetal present in the glycerol and with 
the ester to allow chemoselective removal; in our first approach we chose to explore 
the use of chloroacetate protecting groups which are usually  removed under very 
mild basic conditions (Et3N/water mixture) or using a mild nucleophile (an example 
Scheme 44. DMF α-adduct is an intermediate of the glycosylation reaction.
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would be urea). Under these conditions the ester functionality in the glycerol would 
be expected to remain intact.
4.3. Synthesis Of αGalDAG.
The synthesis of the required 2,3,4,5-benzyl-galactose was achieved starting from 
commercially available β-galactose pentaacetate, which, on activation with BF3.OEt2 
at 0 °C in the presence of EtSH afforded thioglycoside 102 in excellent yield as a 1:1 
mixture of anomers [Scheme 30].[142] The acetate groups were then removed with a 
sub-stoichiometric amount of NaOMe in MeOH to afford the fully deprotected 
thioglycoside 103 after work-up. The work-up  consisted of neutralising the reaction 
mixture with an acidic Dowex ion exchange resin which exchanges the Na cations in 
the reaction mixture with an equivalent amount of protons. Proceeding in this way, 
and once the resin was removed by filtration and the methanol evaporated under 
reduced pressure, the fully deprotected thioglycoside 103 was collected as a white 
foam without the need for further purification.[142] The very polar tetra-ol 103 was then 
protected with benzyl ethers to provide the thioglycoside 104, which was then 
chemoselectively hydrolysed with N-iodosuccinimide in an acetone/water mixture 
(10:1) to yield the hemiacetal 104 as our sugar donor precursor as a 1:1 mixture of 
diastereoisomers.[143, 144] The product was characterised by  HMRS, and the 1:1 ratio 
of diastereoisomers was evidenced in the 1H NMR and in the 13C NMR spectra; the 
diastereomeric OH proton signals appeared in the 1H NMR spectrum at 2.93 and 
3.15 ppm and they integrated as 0.5 H indicative of a 1:1 diastereomeric ratio. The IR 
spectrum showed the OH stretch as further evidence of the acetal hydrolysis.
Towards the Synthesis of α-Galactosyl Diacylglycerol
100
With 104 in hand, we were ready to proceed to the glycosylation step. Shingu et al. 
reported that these glycosylation conditions scrambled the stereochemistry of the 
acceptor 93. Such epimerisation presumably comes from an acid-catalysed acetal 
migration [Scheme 46].
Initially, we performed the reaction under the reported conditions [Scheme 47].[140] 
The hemiacetal 104 was treated with Ph3P and CBr4 at r.t. for four hours. TMU, 
Et4NBr and the acceptor 93 were then added sequentially. TLC  analysis showed that 
the reaction was complete after 24 hours as evidenced by the disappearance of the 
starting material. The NMR spectra of the crude reaction mixture were too complex to 
be interpreted accurately  and it was necessary to purify  the product before further 
O
AcO
AcO
AcO
OAc
OAc
O
AcO
AcO
AcO SEt
OAc
EtSH
O
HO
HO
HO SEt
OH
NaOMe
O
BnO
BnO
BnO SEt
OBn
O
BnO
BnO
BnO OH
OBn
i) NaH
ii) BnBr
NIS / water
acetone
102, 91% 103, quant.
104, 85%105, 75%
Scheme 45. Synthesis of 2,3,4,6-tetrabenzyl-D-galactose 105.
BF3.OEt2
HO
O
O H
+
HO OH
O
OH
O
O
+H
Scheme 46. Acid catalysed isopropylidene migration.
Towards the Synthesis of α-Galactosyl Diacylglycerol
101
analysis. We found, as evidenced by the chemical shift of the anomeric carbon in the 
13C NMR spectrum of the mixture of purified products, that the glycosylation favoured 
the α-anomer (approximately 10:1 of α:β ratio);** however, as found by Shingu et al. 
the stereocentre of the glycerol had also been scrambled under the reaction 
conditions providing the α-galactoside 106i as a 1:1 mixture of the two epimers 
[Scheme 47].[140] We reasoned, based on the assumption that this glycosylation is 
irreversible, that since acetal migration was not possible after the glycosylation has 
taken place, the migration must be fast in comparison with the glycosylation rate; 
thus all of the enantiomerically pure acceptor must be converted into a racemic 
mixture prior to reacting with the donor to afford the observed 1:1 mixture of the 
epimers.
We postulated that the acetal migration that was racemising the glycerol acceptor 93 
could be controlled if we employed an acid scavenger during the glycosylation; 
however, we did not know what effect employing a base would have on the 
stereoselectivity or rate of glycosylation. We were therefore delighted to observe that 
acetal migration was completely suppressed when an excess of iPr2EtN was 
employed as a sterically hindered base. We were also pleased to observe that the 
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** The anomeric carbon in 52i resonates at 98 ppm in the 13C NMR spectrum for the α-anomer and at 104 ppm for 
the β-anomer.
base did not show any adverse effects on the stereoselectivity  or rate of the reaction 
and the glycoside 106ii product was obtained in high yield as an inseparable mixture 
of α- and β-products in about 10:1 favouring the desired α-glycoside product 
[Scheme 48]. We were unable to measure an accurate ratio of the two products due 
to substantial peak overlap  in the 1H NMR spectrum of the crude mixture and on the 
purified mixture of α- and β-products and consequently, a rough estimate was 
obtained from the 13C  NMR spectrum of the crude reaction mixture. The product was 
confirmed by HRMS and the characteristic α-anomeric proton in the 1H NMR 
spectrum at 4.99 ppm integrating as one H. The 13C NMR spectrum showed the 
characteristic α-anomeric carbon environment at 98 ppm as further diagnostic data.
We were encouraged by these results and stereoselectivity, and although the α- and 
β-isomers were inseparable by standard chromatography, we were confident that we 
could accomplish their separation at a later stage in the synthesis. Mindful that the 
acyl chains on the target αGalDAGs feature unsaturation that is incompatible with 
the hydrogenolysis of benzyl ether protecting groups, we planned a protecting group 
exchange before the acylation steps. We therefore took the α- and β-mixture of 
anomers forward to the debenzylation step. Hydrogenolysis of the benzyl ethers in 
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106ii in MeOH or EtOH/THF or THF using either Pd/C  or Pd(OH)2/C under an 
atmosphere of H2 provided the fully debenzylated product but unfortunately  the 
isopropylidene group on the glycerol fragment was also removed under these 
reaction conditions. The deprotection of the acetal is likely to be promoted by the 
generation of a small amount of acid under the hydrogenolysis conditions although 
we were unable to determine its specific identity. We were pleased to see that 
employing DMF as a solvent in the hydrogenolysis provided the debenzylated 
product 107, and this time only  a small amount of acetal removal was observed by 
TLC analysis.we were unable to find any precedent for this observation; however, we 
propose that DMF acts as a weak base for the adventitious acid generated in this 
reaction, thereby suppressing the acetal hydrolysis.
The protecting groups chosen to re-protect the alcohols in 107 needed to be 
orthogonal to the acetal, and to the esters that would be present in the final product. 
We therefore protected the tetra-ol 107 with chloroacetates which can be removed 
selectively under very  mildly  basic conditions allowing us to retain other ester 
functionalities, including those in our αGalDAG targets. The chloroacetate protection 
was achieved in pyridine with chloroacetic anhydride as the acylating agent.[145] 
Pleasingly, the two chloroacetyl-protected anomers had sufficiently different Rf on 
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silica gel to allow the small amount of β-anomer to be separated from the desired α-
anomer 108 by standard silica gel chromatography [Scheme 50]. The product was 
confirmed by HRMS and the 1H NMR spectrum showed the anomeric proton at 5.27 
ppm with a coupling constant of 3.7 Hz.
The diol 109 was readily obtained after Ce(OTf)3-mediated hydrolysis of the acetal in 
MeNO2 saturated with water [Scheme 50]. We anticipated that selective acylation of 
the primary alcohol in 109 could be achieved in the presence of a DCC coupling 
reagent on steric grounds employing one molar equivalent of the corresponding fatty 
acid. However, we were also aware of the migratory aptitude of esters on 1,2-glycerol 
diols.[146, 147] Diacyl glycerols in Nature are found as mixtures of 1,2-diacyl and 1,3-
diacyl glycerols and the ratio usually favours the more thermodynamically stable, 
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namely the 1,3-diacyl glycerol.[148] When we performed the mono acylation of 109 
with oleic acid in the presence of DCC we obtained a mixture that largely favoured 
the acylation of the primary alcohol albeit in poor yield (35-40%) [Scheme 51]. We 
determined by analysis of the 1H NMR spectra of the crude products, a ratio of 15:1 
of primary acylation against acylation of the secondary alcohol in 109, the later 
possesses a characteristic shift downfield of the CH proton in the glycerol appearing 
5.2 ppm as a multiplet. The mass balance included diacyl glycerol and unidentified 
by-products, as well as approximately 10% of starting diol 109. The low yield was 
even worse for the second acylation. The mass recovery as the diacylglycerol after 
the second acylation was approximately  30%. We hypothesised that some of the 
chloroacetate protecting groups may be removed under the acylation conditions 
(DCC coupling generates a urea by-product that may be sufficiently nucleophilic to 
attack the chloroacetate protecting groups) and this position could subsequently be 
acylated under the esterification conditions. We could not confirm our hypothesis and 
several attempts proceeding promptly after quick flash chromatography to avoid long 
exposure of the products to silica gel that might induce chloroacetate removal or acyl 
migration we obtained the products in moderate yield over the two steps.
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BbGL-IIc was purified successfully  by  flash column chromatography and was 
supplied to our collaborators in Harvard University for further testing and assays with 
iNKT cells. We have not obtained the results from these bioassays. 
However, BbGL-IIf could not be totally  purified by flash column chromatography. 
Figure 22 shows 1H NMR spectra of BbGL-IIf after standard flash column 
chromatography purification (spectrum in blue) and after re-purification (spectrum in 
red). The black rectangles enclose the more significant impurities signals in the 1H 
NMR spectrum before and after re-purification. We werenʼt able to identify  this 
fatty acid(R1),
BbGL-IIc (R1: oleic acid, R2: palmitic acid), 44% from 109
fatty acid (R2),
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cat. DMAP
DCC, cat. DMAP
O
HO
HO
HO
OH
O
O
O R1
O
R2
O
O
O
O
O
O
O OH
OH
O
Cl
O
Cl
O
Cl
OCl
O
O
O
O
O
O O
OH
O
Cl
O
Cl
O
Cl
OCl
R1
O
O
O
O
O
O
O O
O
O
Cl
O
Cl
O
Cl
OCl
R1
O
R2
O
BbGL-IIf (R1: linoleic acid, R2: oleic acid), 33% from 109
Scheme 51. Synthesis of αGalDAG targets from diol 109.
109
Et3N, MeOH
CH2Cl2, H2O
Towards the Synthesis of α-Galactosyl Diacylglycerol
107
impurity and an attempt to purify the product further by HPLC proved unsuccessful 
due to the low UV absorption which hindered the detection of BbGL-IIf.
Figure 22. 1H NMR spectrum of BbGL-IIf after standard purification by silica gel flash column 
chromatography (blue spectrum) and re-purification (red spectrum).
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CONCLUSIONS AND FUTURE WORK
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V. CONCLUSIONS AND FUTURE WORK
5.1. Synthesis Of Threitol Ceramide And Labelled Analogues Conclusions.
We have developed a novel synthesis of ThrCer, and have successfully introduced a 
14C label to facilitate immunological studies in mice which are focusing on 
understanding the intracellular trafficking and uptake of this novel glycolipid. We have 
also designed and synthesised the novel glycolipid biotin-ThrCer 84. Preliminary 
immunological assays have shown that this conjugate exhibits a very similar CD1d-
mediated immunoresponse to the unlabelled ThrCer, which makes it a valuable 
chemical tool for studying in vitro and in vivo tissue distribution of this glycolipid in 
mice and in humans.
5.2. Towards The Synthesis Of α-Galactosyl Diacylglycerol Conclusions.
We have developed a stereoselective synthesis of diol 109, which is a key advanced 
intermediate in the synthesis of αGalDAG. The target glycoside BbGL-IIc was 
obtained in three steps from this intermediate, however BbGL-IIf that possesses a 
sensitive-to-oxidation fatty acid–linoleic acid–could not be obtained with high purity in 
the same way. After various purification attempts we proposed that these targets can 
be achieved from the precursor 106 employing other orthogonal ester protecting 
groups or different acylation conditions. Unfortunately under the time restrictions we 
did not have time to explore these possibilities.
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5.3. Future Work.
In the future, our group will focus on the synthesis of Alexa Fluor® fluorophore 
labelled αGalCer and ThrCer for in vivo immunological assays. Our syntheses of 14C 
radiolabelled ThrCer and biotin-labelled ThrCer described here will provide valuable 
knowledge for the retrosynthetic analysis and forward syntheses of these expensive 
labels. In particular, we identified an attachment point next to the amide on the acyl 
chain, which is remote from the hydroxyl functional groups that are known to be 
important for the recognition of CD1d-lipid complex by the TCRs,[50] and at which 
attachment point our results demonstrated that a triazole can effectively attach a 
PEG spacer for elaborating the label.
The stereoseletive synthesis of αGalDAGs is an ongoing project in our lab  and future 
work will capitalise on our findings and will probably focus on the orthogonal 
protection of α-Galactosyl glycerol; for example, protecting the galactose moiety with 
levulinic protecting groups, or the identification of a mild acylation strategy of 109 that 
is compatible with the chloroacetate protecting groups on the galactose moiety to 
suppress the loss of material in side-reactions.
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VI. EXPERIMENTAL SECTION
6.1. General Experimental.
Optical rotations were measured using an Optical Activity PolAAr2001 automatic 
polarimeter. Melting points were determined using open capillaries on a Gallenkamp 
MPD350 melting point apparatus and are uncorrected. Infrared spectra were 
recorded either neat as thin films between NaCl discs, on a Perkin Elmer 1600 FTIR 
spectrometer, or neat on a Perkin Elmer Spectrum 100 fitted with a universal ATR 
accessory. The intensity of each band is described as s (strong), m (medium) or w 
(weak), and with the prefix v (very) and suffix br (broad) where appropriate. 1H-NMR 
spectra were recorded at 500 MHz, 400 MHz, or 300 MHz, using Bruker DRX 500, 
Bruker AMX 400, Bruker AV 400, Bruker AV 300 and Bruker AC  300 spectrometers. 
13C-NMR spectra were recorded at 125 MHz, 100 MHz, or 75 MHz, respectively, 
using Bruker DRX 500, Bruker AMX 400, Bruker AV 400, Bruker AV 300 and Bruker 
AC 300 spectrometers. Chemical shifts are reported as values (ppm) referenced to 
the following solvent signals: CHCl3, δH 7.26; CDCl3, δC 77.0; CH3OH, δH 3.34; 
CD3OD, δC 49.9. The term “stack” is used to describe a region where resonances 
arising from non-equivalent nuclei are coincident, and multiplet, m, to describe a 
region where resonances arising from a single nucleus (or equivalent nuclei) are 
coincident but coupling constants cannot be readily assigned. Mass spectra were 
recorded on a Micromass LCT spectrometer utilising electrospray ionisation (and a 
MeOH mobile phase), and are reported as (m/z (%)). HRMS were recorded on a 
Micromass LCT spectrometer using a lock mass incorporated into the mobile phase.
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All reagents were obtained from commercial sources and used without further 
purification unless stated otherwise. Anhydrous solvents were purchased from 
Sigma-Aldrich UK, stored over 4 Å molecular sieves and under an Ar atmosphere. All 
solutions are aqueous and saturated unless stated otherwise.
Reactions were monitored by  TLC using pre-coated aluminium-backed ICN silica 
plates (60A F254) and visualised by UV detection (at 254 nm) and staining with 5% 
phosphomolybdic acid in EtOH (MPA spray). Column chromatography was 
performed on Merck silica gel (particle size 40-63 m mesh) or Fluka 60 (40-60 m 
mesh) silica gel. Radiograms were produced by 2.5 minutesʼ exposure of Kodak X-
Omat AR films to the TLC plates in the dark.
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6.2. 1-O-(tert-Butyldiphenylsilyl)-2,3-O-benzylidene-L-threitol 53
A solution of (-)-2,3-O-benzylidene-L-threitol (1.00 g, 2.23 mmol) in THF (7 mL) was 
added dropwise over 5 min to a suspension of NaH (60% dispersion in mineral oil, 98 
mg, 2.45 mmol) in THF (10 mL) at 0 °C. After 30 min, a solution of TBDPSCl (674 
mg, 2.45 mmol) in THF (7 mL) was added dropwise over 15 min. After stirring at r.t. 
for 12 h, the reaction was quenched by the sequential addition of MeOH (2 mL) and 
NaHCO3 solution (20 mL). The phases were separated and the aqueous phase was 
washed with CH2Cl2 (3 × 20 mL). The combined organic phases were washed with 
brine (20 mL), dried (MgSO4), filtered and the solvent was evaporated under reduced 
pressure. The residue was purified by  silica gel flash column chromatography 
(eluent: 20% EtOAc in hexanes) to provide silyl ether 53 as a colourless oil (1:1 
mixture of diastereoisomers, 919 mg, 71%). Data on diastereoisomeric mixture: Rf = 
0.25 (20% EtOAc in hexanes); νmax (film)/cm-1 3432br (OH), 3070m, 2930s, 2858s, 
1654w, 1589w, 1471m, 1427m, 1390m, 1361m, 1310m, 1218m, 1112s, 1027m, 
998m, 917m; δH (300 MHz, CDCl3) 1.07 (4.5H, s, (CH3)3CSi), 1.09 (4.5H, s, 
(CH3)3CSi), 1.96-2.05 (1H, stack, CH2OH), 3.70-3.96 (4H, stack), 4.11-4.25 (1.5H, 
stack), 4.32-4.37 (0.5H, m), 5.96 (0.5H, s, PhCH), 5.99 (0.5H, s, PhCH), 7.35-7.50 
O O
TBDPSO OH
Chemical Formula: C27H32O4Si
Molecular Weight: 448.63
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(11H, stack, Ph), 7.65-7.72 (4H, stack, Ph); δC (75 MHz, CDCl3) [19.1 (quat. C, 
(CH3)3CSi), 19.2 (quat. C, (CH3)3CSi)], [26.72 (CH3, (CH3)3C), 26.75 (CH3, (CH3)3C)], 
[62.7 (CH2, CH2O), 62.8 (CH2, CH2O)], [63.9 (CH2, CH2O), 64.0 (CH2, CH2O)], [77.8 
(CH, CHO), 78.7 (CH, CHO), 79.6 (CH, CHO), 79.9 (CH, CHO)], [103.7 (CH, PhCH), 
104.1 (CH, PhCH)], [126.52 (CH, Ph), 126.58 (CH, Ph), 127.73 (CH, Ph), 127.77 
(CH, Ph), 128.26 (CH, Ph), 128.37 (CH, Ph), 129.3 (CH, Ph), 129.5 (CH, Ph), 129.79 
(CH, Ph), 129.81 (CH, Ph), 129.82 (CH, Ph), 129.85 (CH, Ph)], [132.81 (quat. C, 
ipsoPh), 132.85 (quat. C, ipsoPh)], [135.49 (CH, Ph), 135.53 (CH, Ph)], [137.2 (quat. 
C, ipsoPh), 137.4 (quat. C, ipsoPh)], some resonances overlapped in the aromatic 
region; m/z (TOF ES+) 471.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 471.1972 ([M
+Na]+. C27H32O4SiNa requires 471.1968).
6.3. (2S, 3S, 4R)-2-Azido-1,3,4-octadecanetriol 54[46, 149]
TfN3 was freshly prepared prior to the reaction as follows: NaN3 (12.5 g, 192 mmol) 
was dissolved in a minimum volume of H2O (35 mL, solubility of NaN3 in H2O is ~ 0.4 
g mL-1) and cooled to 0 °C. CH2Cl2 (35 mL) was added, followed by dropwise 
addition over 15 min of Tf2O (15.92 mL, 96 mmol) with vigorous stirring of the 
solution. The flask was stoppered and stirring continued at 0 °C. After 2 h, NaHCO3 
solution (30 mL) was carefully  added while stirring was continued until gas evolution 
HO
N3
OH
OH
Chemical Formula: C18H37N3O3
Molecular Weight: 343.505
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had ceased. The reaction contents were then transferred to a separating funnel and 
the phases were separated. The aqueous phase was washed with CH2Cl2 (2 × 25 
mL). The combined organic phases were washed with a NaHCO3 solution (1 × 30 
mL). The resulting solution of TfN3 in CH2Cl2 was used in the azidation step without 
further purification as follows: Amine 52 (10.0 g, 31.5 mmol) and CuSO4·5H2O (32 
mg, 0.13 mmol) were dissolved in water (85 mL). The CH2Cl2 solution of TfN3 (85 
mL) was then added with vigorous stirring. MeOH (570 mL) was then added over 5 
min. After 18 h, the reaction mixture was diluted with H2O (260 mL) and extracted 
with EtOAc (3 × 260 mL). The combined organic phases were filtered through a silica 
plug and washed with EtOAc until complete elution of the product. Removal of the 
solvent under reduced pressure afforded azide 54 as a white solid (10.6 g, 98%). 
Data: Rf = 0.7 (eluent: EtOAc); mp 92 – 94 °C [lit. 91 - 92 °C];[46] [α]25D + 9.6 (c = 1.0, 
CHCl3) [lit. [α]25D + 10 (c = 1, CHCl3)];[149] νmax(film)/cm-1 3683m (OH), 3390m (OH) 
3328m (OH), 3020s, 2918m, 2847m, 2108m (N3), 1602w, 1521m, 1462w, 1410m, 
1355m, 1215s, 1148m, 1071w, 1014w, 929m, 849w; δH (300 MHz, CDCl3/CD3OD, 
2:1) 0.66 (3H, t, J 6.5, CH3CH2), 0.95-1.22 (24H, stack, CH2), 1.37-1.42 (2H, stack, 
CH(OH)CH2CH2), 3.34-3.39 (3H, stack), 3.58 (1H, dd, J 6.1, 5.7), 3.72 (1H, dd, J 3.9, 
3.7); δC (75 MHz, MeOD) 14.4 (CH3, CH2CH3), 23.7 (CH2), 26.7 (CH2), 30.5 (CH2), 
30.7 (CH2), 30.8 (CH2), 33.1 (CH2), 33.9 (CH2), 62.5 (CH2, CH2OH), 66.6 (CH, 
CHN3), 72.9 (CH, CHOH), 76.0 (CH, CHOH), some resonances overlapped in the 
alkyl region;[149] m/z (TOF ES+) 366.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
366.2728 ([M+Na]+. C18H37N3O3Na requires 366.2733).
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6.4. (2S, 3S, 4R)-2-Azido-3,4-O-isopropylidene-1,3,4-octadecanetriol 56[47]
Sc(OTf)3 (286 mg, 0.58 mmol) was added to a suspension of triol 54 (2.0 g, 5.82 
mmol) in a 1:1 mixture of acetone and 2,2-dimethoxypropane (50 mL) at 0 °C 
resulting in complete dissolution of the solid. The reaction mixture was stirred at this 
temperature for 20 min and then neutralised with Et3N. The solvent was removed 
under reduced pressure and the residue was dissolved in CH2Cl2 (50 mL). The 
solution was washed with NaHCO3 solution (20 mL) and the aqueous phase was 
extracted with CH2Cl2 (3 × 20 mL). The organic fractions were combined, dried 
(Na2SO4), filtered and the solvent was evaporated under reduced pressure to provide 
a mixture of acetals 55 and 56, which was dissolved in CH2Cl2/H2O (40 mL, 10:1) 
and treated with 50% TFA in H2O (432 µL, 5.82 mmol). After 10 min, TLC  analysis 
showed that the acyclic acetal in 55 had been chemoselectively  hydrolysed. The 
reaction mixture was neutralised with Et3N and diluted with NaHCO3 solution (20 
mL). The phases were separated and the aqueous phase was extracted with CH2Cl2 
(2 × 20 mL). The combined organic phases were dried (MgSO4), filtered and the 
solvent removed under reduced pressure. Purification of the residue by  flash column 
chromatography (eluent: 20% EtOAc in hexanes) afforded the acetonide 56 as a 
white, low-melting-point, amorphous solid (1.95 g, 87%). Data: Rf = 0.3 (eluent: 25% 
EtOAc in hexanes); [α]25D + 23 (c = 1.0, CHCl3); νmax (film)/cm-1 3440br (OH), 2925s, 
HO
N3
O
O
Chemical Formula: C21H41N3O3
Molecular Weight: 383.569
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2854s, 2100s (N3), 1465m, 1370m, 1247m, 1217m, 1169m, 1063br, 870w, 758s; δH 
(300 MHz, CDCl3) 0.88 (3H, t, J 6.0, CH3CH2), 1.26-1.30 (23H, stack), 1.34 (3H, s, 1 
× C(CH3)2), 1.43 (3H, s, 1 ×  C(CH3)2), 1.50-1.63 (3H, stack), 2.08 (1H, t, J 6.0, 
CH2OH), 3.44-3.50 (1H, m), 3.83-3.91 (1H, m), 3.94-4.03 (2H, stack), 4.15-4.21 (1H, 
m); δC (75 MHz, CDCl3) 14.1 (CH3, CH3CH2), 25.5 (CH3, 1 × C(CH3)2), 26.5 (CH2), 
28.0 (CH3, 1 × C(CH3)2), 29.35 (CH2), 29.41 (CH2), 29.53 (CH2), 29.58 (CH2), 29.59 
(CH2), 29.65 (CH2), 29.68 (CH2), 29.69 (CH2), 31.9 (CH2), 61.2 (CH, CHN3), 63.9 
(CH2, CH2OH), 76.6 (CH, CHO), 77.7 (CH, CHO), 108.7 (quat. C, C(CH3)2), some 
resonances overlapped in the alkyl region, the spectroscopic data agree with those of 
the lit.;[47] m/z (TOF ES+) 406.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 406.3033 
([M+Na]+. C21H41N3O3Na requires 406.3046).
6.5. 1-O-[1-O-(tert-Butyldiphenylsilyl)-2,3-O-benzylidene-L-threitol]-2-azido-3,4-
O-isopropylidene-1,3,4-D-ribo-octadecantriol 46
Tf2O (329 µL, 1.96 mmol) was added dropwise over 10 min to a solution of alcohol 
53 (1:1 mixture of diastereoisomers, 878 mg, 1.96 mmol) and 2,6-di-tert-butylpyridine 
(484 µL, 2.16 mmol) in CH2Cl2 (20 mL) at 0 °C. After 1 h, the reaction mixture was 
diluted with CH2Cl2 (20 mL) and the resulting solution washed sequentially  with cold 
Chemical Formula: C48H71N3O6Si
Molecular Weight: 814.179
O
N3
O
OO
O
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H2O (2 × 50 mL) and brine (10 mL), dried (MgSO4) and filtered. Removal of the 
solvent under reduced pressure and purification of the residue by flash column 
chromatography (eluent: 5% EtOAc in hexanes containing drops of Et3N) yielded 
triflate 49 as a colourless oil (1:1 mixture of diastereoisomers, 870 mg, 85%). The 
triflate was unstable and used immediately. Selected data on diastereoisomeric 
mixture: Rf = 0.3 (5% EtOAc in hexanes); δH (300 MHz, CDCl3) 1.07 (4.5H, s, 
(CH3)3CSi), 1.09 (4.5H, s, (CH3)3CSi), 3.81-3.99 (2H, stack), 4.11-4.17 (1H, stack), 
4.41-4.45 (0.5H, m), 4.52-4.61 (1.5H, stack), 4.69-4.75 (1H, stack), 5.95 (0.5H, s, 
PhCH), 6.03 (0.5H, s, PhCH), 7.36-7.48 (11H, stack, Ph), 7.63-7.70 (4H, stack, Ph).
A solution of Alcohol 56 (575 mg, 1.5 mmol) in THF (10 mL) was treated with NaH 
(60% in mineral oil, 64 mg, 1.6 mmol) at 0 °C. After 1 h, a solution of triflate 49 (870 
mg, 1.5 mmol) in THF (5 mL) was added dropwise over 5 min. The resulting solution 
was stirred at this temperature for 1 h and then at r.t. for 12 h. The reaction was then 
quenched by the addition of MeOH (2 mL) followed by NaHCO3 solution (10 mL). The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (3 × 20 
mL). The combined organic fractions were washed with brine (15 mL) and dried 
(MgSO4), filtered and the solvent was removed under reduced pressure. The residue 
was purified by flash column chromatography (eluent: 5% EtOAc in hexanes) to 
provide ether 46 as a colourless oil (1:1 mixture of diastereoisomers, 1.13 g, 92%). 
Data on diastereoisomeric mixture: Rf = 0.35 (5% EtOAc in hexanes); νmax(film)/cm-1 
3071w, 2926s, 2855s, 2098s (N3), 1589w, 1461m, 1427m, 1379m, 1220m, 1112s, 
874w; δH (300 MHz, CDCl3) 0.85 (3H, t, J 6.6, CH3CH2), 1.06 (4.5H, s, (CH3)3CSi), 
1.09 (4.5H, s, (CH3)3CSi), 1.24-1.41 (32H, stack), 3.55-3.63 (1H, stack), 3.67-4.01 
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(7H, stack), 4.09-4.17 (1.5H, stack), 4.23-4.33 (1H, stack), 4.42-4.46 (0.5H, m), 5.99 
(0.5H, s, PhCH), 6.00 (0.5H, s, PhCH), 7.33-7.51 (11H, stack, Ph), 7.66-7.73 (4H, 
stack, Ph); δC (75 MHz, CDCl3) 14.1 (CH3, CH3CH2), 19.2 (quat. C, (CH3)3CSi), 22.7 
(CH2), [25.6 (CH3, 1 × C(CH3)2), 25.7 (CH3, 1 × C(CH3)2], 26.4 (CH2), [26.82 (CH3, 
C(CH3)3, 26.86 (CH3, C(CH3)3], [28.1 (CH3, 1 × C(CH3)2, 28.2 (CH3, 1 × C(CH3)2], 
29.3 (CH2), 29.41 (CH2), 29.45 (CH2), 29.53 (CH2), 29.57 (CH2), 29.59 (CH2), 29.6 
(CH2), 29.7 (CH2), 31.9 (CH2), [59.8 (CH, CHN3), 59.9 (CH, CHN3)], [64.2 (CH2, 
CH2O), 64.3 (CH2, CH2O)], [72.0 (CH2, CH2O), 72.2 (CH2, CH2O)], [72.89 (CH2, 
CH2O), 72.94 (CH2, CH2O)], 75.6 (CH, CHO), [77.7 (CH, CHO), 77.8 (CH, CHO)], 
[77.9 (CH, CHO), 78.0 (CH, CHO)], [78.7 (CH, CHO), 78.8 (CH, CHO)], [104.0 (CH, 
PhCH), 104.3 (CH, PhCH)], [108.2 (quat. C, C(CH3)2), 108.3 (quat. C, C(CH3)2)], 
[126.7 (CH, Ph), 126.8 (CH, Ph)], [127.70 (CH, Ph), 127.74 (CH, Ph)], [128.2 (CH, 
Ph), 128.3 (CH, Ph)], [129.25 (CH, Ph), 129.34 (CH, Ph)], 129.73 (CH, Ph), 129.74 
(CH, Ph), 129.77 (CH, Ph), 133.02 (quat. C, ipsoPh), 133.05 (quat. C, ipsoPh), 
133.06 (quat. C, ipsoPh), 133.09 (quat. C, ipsoPh), 135.6 (CH, Ph), [137.4 (quat. C, 
ipsoPh), 137.5 (quat. C, ipsoPh), some resonances overlapped in the alkyl region; m/
z (TOF ES+) 836.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 836.5041 ([M+Na]+. 
C48H71N3O6SiNa requires 836.5010).
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6.6. 1-O-[2,3-O-benzylidene-L-threitol]-2-azido-3,4-O-isopropylidene-1,3,4-D-
ribo-octadecantriol 48
TBAF (1 M solution in THF, 1.4 mL, 1.4 mmol) was added to a solution of silyl ether 
46 (1.10 g, 1.35 mmol) in THF (15 mL) at r.t. After 4 h, NH4Cl solution (10 mL) was 
added. The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 10 mL). The solvent was removed under reduced pressure and the 
residue purified by flash column chromatography (eluent: 25% EtOAc in hexanes) to 
provide alcohol 48 as a colourless oil (1:1 mixture of diastereoisomers, 740 mg, 
95%). Data on diastereoisomeric mixture: Rf = 0.35 (30% EtOAc in hexanes); νmax 
(film)/cm-1 3463br (OH), 2924s, 2853s, 2099s (N3), 1459m, 1379m, 1246m, 1220m, 
1092m, 1065m, 1027m, 869w; δH (300 MHz, CDCl3) 0.88 (3H, t, J 6.6, CH3CH2), 
1.23-1.31 (28H, stack), 1.35-1.41 (3H, stack), 1.45-1.60 (1H, stack), 1.96-2.04 (1H, 
stack, OH), 3.53-3.60 (1H, stack), 3.67-3.98 (7H, stack), 4.08-4.31 (3H, stack), 5.97 
(0.5H, s, PhCH), 6.00 (0.5H, s, PhCH), 7.37-7.40 (3H, stack, Ph), 7.48-7.51 (2H, 
stack, Ph); δC (75 MHz, CDCl3) 14.0 (CH3, CH2CH3), 22.6 (CH2), [25.5 (CH3, 1 × 
C(CH3)2, 25.6 (CH3, 1 × C(CH3)2], 26.3 (CH2), [28.0 (CH3, 1 × C(CH3)2, 28.1 (CH3, 1 
× C(CH3)2], 29.27 (CH2), 29.33 (CH2), 29.35 (CH2), 29.46 (CH2), 29.51 (CH2), 29.57 
(CH2), 29.6 (CH2), 31.8 (CH2), [59.8 (CH, CHN3), 59.9 (CH, CHN3)], 62.5 (CH2, 
O
N3
O
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Chemical Formula: C32H53N3O6
Molecular Weight: 575.780
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CH2O), [71.5 (CH2, CH2O), 71.6 (CH2, CH2O)], [72.78 (CH2, CH2O), 72.84 (CH2, 
CH2O)], 75.5 (CH, CHO), 76.4 (CH, CHO), 77.2 (CH, CHO), [77.68 (CH, CHO), 77.70 
(CH, CHO)], [79.7 (CH, CHO), 79.9 (CH, CHO)], [103.8 (CH, PhCH), 104.0 (CH, 
PhCH)], [108.20 (quat. C, (CH3)2C), 108.23 (quat. C, (CH3)2C)], 126.6 (CH, Ph), 
[128.2 (CH, Ph), 128.3 (CH, Ph)], [129.3 (CH, Ph), 129.4 (CH, Ph)], [137.2 (quat. C, 
ipsoPh), 137.4 (quat. C, ipsoPh), some resonances overlapped in alkyl region; m/z 
(TOF ES+) 598.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 598.3805 ([M+Na]+. 
C32H53N3O6Na requires 598.3832).
6.7. 1-O-[L-Threitol]-2-amino-1,3,4-D-ribo-octadecantriol 47
Ce(OTf)3 (117 mg, 0.20 mmol) was added to a vigorously stirred solution of acetal 48 
(200 mg, 0.32 mmol) in MeNO2 (saturated with H2O, 3 mL) and CH2Cl2 (2 mL). After 
4 h at r.t., the reaction mixture was diluted with CH2Cl2 (5 mL) and NaHCO3 solution 
(10 mL) was added. The aqueous phase was extracted with CH2Cl2 (10 mL) and the 
organic phases were combined and washed with brine (5 mL) and then dried 
(Na2SO4). The solvent was removed under reduced pressure. The residue (yellowish 
paste) was dissolved in MeOH (5 mL) and Pd/C  (30 mg, 32 mol) and AcOH (40 µL, 
0.65 mmol) were added. The reaction vessel was evacuated and then placed under 
an atmosphere of H2. The suspension was stirred overnight. The reaction mixture 
O
NH2
OH
OHOH
OH
HO
Chemical Formula: C22H47NO6
Molecular Weight: 421.61
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was filtered and the filtrate was concentrated under reduced pressure. The residue 
was purified by column chromatography (eluent: 10% MeOH in CHCl3 to 50% MeOH 
in CHCl3) to afford amine 47 as a white foam (72 mg, 50%). Data: Rf = 0.1 (20% 
MeOH in CHCl3); δH (300 MHz, CDCl3) 0.79 (3H, t, J 6.7, CH2CH3), 1.08-1.32 (23H, 
stack, alkyl chain), 1.38-1.50 (1H, m), 1.55-1.69 (2H, m), 3.14-3.21 (1H, m), 
3.25-3.65 (9H, stack), 3.68-3.75 (1H, m), exchangeable protons were exchanged 
with deuterium from CD3OD for clarity prior to running the 1H-NMR spectrum; δC (75 
MHz, CDCl3) 13.9 (CH3, CH2CH3), 22.5 (CH2), 25.6 (CH2), 29.2 (CH2), 29.6 (CH2), 
31.8 (CH2), 33.5 (CH2), 52.9 (CH), 63.4 (CH2), 70.1 (CH), 71.0 (CH2), 71.6 (CH), 72.5 
(CH2), 73.2 (CH), 73.9 (CH), some resonances overlapped in alkyl region; m/z (TOF 
ES+) 422.3 ([M+H]+, 100%); HRMS m/z (TOF ES+) 422.3489 ([M+H]+. C22H48NO6, 
requires 422.3482).
6.8. 1-O-[L-Threitol]-2-hexacosanoylamino-1,3,4-D-ribo-octadecantriol 39[51]
Hexacosanoic acid (37.6 mg, 94.9 mol) was placed in (COCl)2 (1.0 mL) and the 
resulting solution stirred at 70 °C for 2 h, after which time, the solution was cooled to 
r.t. and the (COCl)2 was removed under a stream of dry argon. The residual volatiles 
O
5
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Chemical Formula: C48H97NO7
Molecular Weight: 800.29
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were removed under reduced pressure. The resulting crude acyl chloride was 
dissolved in THF (500 μL) and added with vigorous stirring to a solution of amine 47 
(20 mg, 47 μmol) in THF/NaOAc(aq) (8 M, 800 μL, 1:1). Vigorous stirring was 
maintained for 2 h, after which time, the mixture was left to stand and the phases 
were separated. The aqueous phase was extracted with THF (2 × 1 mL) and the 
combined organic phases were evaporated under reduced pressure. Purification of 
the residue by column chromatography (gradient from CHCl3 to 15% MeOH in 
CHCl3) afforded threitol ceramide 39 as a white solid (23 mg, 60%). Data: Rf = 0.3 
(8% MeOH in CHCl3); mp 107 - 109 °C; [α]D (the insolubility of this amphiphilic 
compound at r.t. prevented us from obtaining reliable optical rotation data); νmax (neat 
disc)/cm-1 3308br m (OH, NH), 2915s, 2849s, 2098w, 1634m (C=O), 1540m, 1471m, 
1108m, 1070m, 1026m, 718m; δH (500 MHz, d8-THF, 45 °C) 0.89 (6H, app t, J 6.7, 2 
× CH2CH3), 1.25-1.63 (72H, stack, alkyl chain), 2.12 (2H, t, J 7.7, C(O)CH2), 
3.40-3.47 (2H, stack, C(7)H, C(8)H), 3.47-3.57 (5H, stack, C(4)H2, C(1)H2, C(3)H or 
C(2)H), 3.59-3.63 (1H, m, C(5)HaHb), 3.67-3.72 (2H, stack, C(5)HaHb, C(2)H or 
C(3)H), 4.14-4.18 (1H, m, C(6)H), 6.93-6.96 (1H, m, NH); δC (125 MHz, d8-THF, 45 
°C) 14.3 (CH3, 2 × CH2CH3), [23.5 (CH2), 26.6 (CH2), 26.8 (CH2), 29.3 (CH2), 30.3 
(CH2), 30.5 (CH2), 30.59 (CH2), 30.64 (CH2), 30.7 (CH2), 30.8 (CH2), 32.8 (CH2), 34.1 
(CH2), some alkyl resonances overlapped], 36.9 (CH2, C(O)CH2), 51.8 (CH, C(6)), 
64.6 (CH2, C(1)), 71.3 (CH, C(2) or C(3)), 71.5 (CH2, C(5)), 73.0 (CH, C(8)), 73.1 
(CH, C(3) or C(2)), 74.1 (CH2, C(4)), 76.7 (CH, C(7)), 173.0 (quat. C, C=O), the 
spectroscopic data were not directly  comparable with those of the lit. as those were 
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measured in deuterated pyridine;[51] m/z (TOF ES+) 822.7 ([M+Na]+, 100%); HRMS 
m/z (TOF ES+) 822.7175 ([M+Na]+. C48H97NO7Na requires 822.7163).
6.9. Pentacos-10-yn-1-ol 59
nBuLi (2.5 M solution in hexanes, 8.72 mL, 21.8 mmol) was added dropwise over 40 
min to a solution of 10-undecyn-1-ol 57 (1.75 g, 10.4 mmol) in THF (21 mL) 
containing HMPA (7.68 mL, 41.6 mmol) at -78 °C. After 15 min, a solution of 1-
bromotetradecane 58 (3.17 g, 11.4 mmol) in THF (2 mL) was added. The reaction 
mixture was stirred at -78 °C for 1 h and then left to warm to r.t. overnight. The 
reaction mixture was then diluted with Et2O (20 mL) and quenched by slow addition 
of H2O (20 mL). The phases were separated and the aqueous phase was extracted 
with Et2O (2 × 20 mL). The combined organic phases were dried with MgSO4 and the 
volatiles were removed under reduced pressure. The residue was purified by column 
chromatography (eluent: 20% Et2O in hexanes) to afford the alkyne 59 as a white 
solid (1.57 g, 40%). Data: Rf = 0.15 (5% EtOAc in hexanes); νmax (neat)/cm-1 3357w 
(OH), 2919s, 2848s, 1459m, 1130w, 1057m, 1036m, 1013m, 975w, 725s; δH (300 
MHz, CDCl3) 0.86 (3H, t, J 6.8, CH3CH2), 1.15-1.60 (38H, stack, alkyl chain), 2.12 
(4H, app. t, J 7.1, CH2CCCH2), 6.63 (2H, app. q, J 5.5, CH2OH), resonance for OH 
not visible; δC (75 MHz, CDCl3) 14.1 (CH3, CH3CH2), 18.8 (CH2), 22.7 (CH2), 25.7 
HO
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(CH2), 28.9 (CH2), 29.2 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 32.0 
(CH2), 32.8 (CH2), 63.1 (CH2, CH2OH), 80.2 (quat. C, CC), 80.3 (quat. C, CC), some 
resonances overlapped in the alkyl region; m/z (TOF ES+) 471.3 ([M+Ag]+, 100%); 
HRMS m/z (TOF ES+) 471.2745 ([M+Ag]+, C25H48OAg requires 471.2756).
6.10. 1-Bromo-pentacosane 61
Pd/C (29 mg, 0.27 mmol) was added to a solution of alkyne 59 (1.0 g, 2.74 mmol) in 
Et2O (10 mL). The reaction vessel was evacuated and replaced with a H2 
atmosphere and then the mixture was stirred overnight. The slurry was then filtered, 
washing the residue with hot THF (2 × 5 mL). The solvent was evaporated under 
reduced pressure to afford alcohol 60 as a white paste (943 mg, 95%). Data: Rf = 
0.15 (5% EtOAc in hexanes); νmax (neat)/cm-1 3278br (OH), 2917s, 2849s, 1473m, 
1452m, 1062m, 731m, 719m; δH (300 MHz, CDCl3) 0.87 (3H, t, J 6.5, CH3CH2), 
1.20-1.37 (44H, stack, alkyl chain), 1.50-1.60 (2H, m, CH2CH2OH), 3.63 (2H, t, J 6.4, 
CH2OH); δC (75 MHz, CDCl3) 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.7 (CH2), 29.38 
(CH2), 29.45 (CH2), 29.7 (CH2), 31.9 (CH2), 32.8 (CH2), 63.1 (CH2, CH2OH), some 
resonances overlapped in alkyl region. Satisfactory mass spectral analysis could not 
be obtained on alcohol 60 and was then used without further purification in the next 
step. PPh3 (531 mg, 2.02 mmol) and CBr4 (492 mg, 1.48 mmol) were added 
sequentially to a solution of alcohol 60 (500 mg, 1.35 mmol) in CH2Cl2 (10 mL) at 0 
Br
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°C. After 1 h, hexanes (10 mL) were added slowly and the resulting precipitate was 
filtered off. The filtrate was diluted with CH2Cl2 (20 mL) and washed with H2O (10 
mL). The phases were separated and the organic phase was dried (Na2SO4). The 
volatiles were evaporated under reduced pressure to afford a residue, which was 
purified by column chromatography  (eluent: 2% Et2O in hexanes) to afford alkyl 
bromide 61 as a white solid (378 mg, 65%). Data: Rf = 0.4 (eluent: hexanes); δH (300 
MHz, CDCl3) 0.88 (3H, t, J 6.6, CH2CH3), 1.20-1.31 (43H, stack, alkyl chain), 
1.39-1.48 (1H, m), 1.79-1.87 (2H, m), 3.40 (2H, t, J 6.9, CH2Br); δC (75 MHz, CDCl3) 
14.1 (CH3, CH2CH3), 22.7 (CH2), 28.2 (CH2), 28.8 (CH2), 29.4 (CH2), 29.5 (CH2), 29.7 
(CH2), 31.9 (CH2), 32.8 (CH2), 34.0 (CH2), some resonances overlapped in alkyl 
region; satisfactory mass spectral analysis could not be obtained for bromide 61.
6.11. [14C]Hexacosan-1-nitrile 62
Alkyl bromide 61 (13 mg, 30 μmol) was added to a solution of Na14CN (1 mg, 20 
µmol, 53 mCi mmol-1 (1.961 GBq mmol-1)) in DMSO (1 mL). The mixture was heated 
at 85 °C  for 72 h and then cooled to r.t. Et2O (1 mL) was added to the mixture 
followed by H2O (1 mL). The phases were separated and the aqueous phase was 
extracted with Et2O (3 × 1 mL). The combined organic phases were dried with 
MgSO4 and the volatiles were removed under reduced pressure. The residue was 
C
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purified by column chromatography (eluent: 5% EtOAc in hexanes) to provide nitrile 
62 (7 mg, 95%). Data: Rf = 0.35 (5% EtOAc in hexanes); νmax (film)/cm-1 2914s (br), 
2848s, 2241w (CN), 1633w, 1471s, 1424w, 1377w, 730w, 716s; δH (300 MHz, CDCl3) 
0.86 (3H, t, J 7.0, CH2CH3), 1.90-1.32 (42H, stack, alkyl chain), 1.35-1.49 (2H, m), 
1.60-1.72 (2H, m), 2.31 (2H, t, J 6.7, CH2CN); δC (75 MHz, CDCl3) 14.1 (CH3, 
CH2CH3), 17.1 (CH2), 22.7 (CH2), 25.4 (CH2), 28.7 (CH2), 28.8 (CH2), 29.3 (CH2), 
29.4 (CH2), 29.5 (CH2), 29.7 (CH2), 30.0 (CH2), 31.9 (CH2), some resonances 
overlapped in the alkyl region; the nitrile resonance not observed; m/z (TOF ES+) 
400.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 400.3932 ([M+Na]+. C26H51NNa 
requires 400.3919); spectroscopic data and mass spectral analyses were taken of 
the nonradiolabelled nitrile; TLC  and radiogram that compared radiolabelled with 
nonradiolabelled product provided confirmation of the radiolabelled nitrile 62.
6.12. [14C]Hexacosanoic acid 63
A solution of NaOH (220 mg, 5.5 mmol) in a mixture of EtOH (2.4 mL) and H2O (0.3 
mL) was prepared. [14C]Nitrile 62 (7 mg, 20 mol) was placed in 1 mL of this solution 
and the mixture was heated at 70 °C  for 6 d, after which time, TLC  indicated that the 
alkyl nitrile had been consumed. The mixture was diluted with H2O (2 mL) and the pH 
reduced to pH = 3 with conc. hydrochloric acid. The solution was extracted with Et2O 
C
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(3 × 2 mL). The phases were separated and the organic fraction was dried (MgSO4). 
The volatiles were evaporated under reduced pressure to afford the fatty acid 63 as a 
white solid (7.0 mg, 95%). Data: Rf = 0.25 (eluent: 30% EtOAc in hexanes); δH (300 
MHz, CDCl3) 0.88 (3H, t, J 6.7, CH2CH3), 1.25-1.35 (44H, stack, alkyl chain), 
1.60-1.69 (2H, m), 2.35 (2H, t, J 6.9, CH2CO2H), carboxylic acid resonance not 
visible; spectroscopic data agree with that from commercially available material; m/z 
(TOF ES-) 395.3 ([M-H]-, 100%); HRMS m/z (TOF ES-) 395.3908 ([M-H]-. C26H51O2 
requires 395.3905); spectroscopic data and mass spectral analyses were taken of 
the nonradiolabelled cerotic acid; TLC and radiogram that compared radiolabelled 
with nonradiolabelled product provided confirmation of the radiolabelled cerotic acid 
63.
6.13. [14C]-1-O-[L-Threitol]-2-hexacosanoylamino-1,3,4-D-ribo-octadecantriol 
[14C]-39
A solution of [14C]hexacosanoic acid [14C]-63 (7.0 mg, 20 μmol ) in (COCl)2 (0.5 mL) 
was stirred at 70 °C  for 2 h, after which time, the solution was cooled to r.t. and the 
(COCl)2 was removed under a stream of dry  Ar. The residual volatiles were removed 
under reduced pressure. The resulting crude acyl chloride (20 μmol, assuming 100% 
O
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conversion) was dissolved in THF (0.5 mL) and added with vigorous stirring to a 
solution of amine 47 (16.8 mg, 40 μmol) in THF/NaOAc(aq) (8 M, 0.8 mL, 1:1). 
Vigorous stirring was maintained for 2 h, after which time, TLC showed that the fatty 
acid had been consumed. The mixture was left to stand and the phases were 
separated. The aqueous phase was extracted with THF (2 × 1.0 mL) and the 
combined organic phases were evaporated under reduced pressure. Purification of 
the residue by column chromatography (eluting a gradient from CHCl3 to 15% MeOH 
in CHCl3) afforded threitol ceramide [14C]-39 as a white solid (13.6 mg, 85%). The 
product characterisation was inferred after TLC  and radiogram of radiolabelled and 
nonradiolabelled products. We could not obtained the data directly from the 
radiolabel compound because of health and safety policies and health concerns.
6.14. α-Bromo cerotic acid 74
A mixture of cerotic acid (200 mg, 0.5 mmol) and red phosphorus (16 mg, 0.5 mmol) 
was heated to 95 °C and Br2 (90 µL, 1.75 mmol) was added dropwise over 1 min at 
this temperature with stirring. The reaction mixture was stirred for 6 h after which time 
the heat was removed and the mixture allowed to cool to r.t. The reaction mixture 
was diluted with Et2O (10 mL) and washed with H2O (10 mL). The aqueous phase 
was extracted with Et2O (2 × 10 mL), and the combined organic fractions were 
HO
O
Br
Chemical Formula: C26H51BrO2
Molecular Weight: 475.586
Experimental Section
131
washed with brine (10 mL), dried with MgSO4, filtered and the solvent was removed 
under reduced pressure. The solid residue was re-crystallised from hexanes to yield 
α-bromo acid 74 as a white solid (160 mg, 67%). Data: Rf = 0.35 (eluent: 30% EtOAc 
in hexanes); mp. = 73 - 74 °C; νmax(film)/cm-1 2915s, 2849s, 1715m (C=O), 1697s 
(C=O), 1476.5w, 1462m, 1429w, 1241w (br), 1164w, 1120w, 906w, 725m, 662m; δH 
(300 MHz, CDCl3) 0.88 (3H, t, J 6.8, CH2CH3), 1.21-1.33 (44H, stack, (CH2)acyl 
chain), 1.95-2.21 (2H, m, CH2CHBr), 4.24 (1H, t, J 7.6, CH2CHBr); δc (75 MHz, 
CDCl3): 14.1 (CH3, CH2CH3), 22.7 (CH2), 27.2 (CH2), 28.8 (CH2), 29.3 (CH2), 29.4 
(CH2), 29.5 (CH2), 29.7 (CH2), 29.8 (CH2), 32.0 (CH2), 34.7 (CH2, CH2CHBr), 45.4 
(CH, CH2CHBr),176.0 (quat. C, C=O), some resonance overlapped on the alkyl 
region; m/z (TOF ES-) 473.3, 475.3 ([M-H]-, 100%); HRMS m/z (TOF ES-) 473.2989 
([M-H]-. C26H50BrO2 requires 473.2994).
6.15. 1-O-[2,3-O-benzylidene-L-threitol]-2-(α-azido-hexacosanoyl)amino-3,4-O-
isopropylidene-1,3,4-D-ribo-octadecantriol 70
O
HN
O
OO
O
HO
Ph
O
N3
Chemical Formula: C58H104N4O7
Molecular Weight: 969.469
Experimental Section
132
Me3P (1 M solution in THF, 1.25 mL, 1.25 mmol) was added to a solution of azide 48 
(700 mg, 1.21 mmol) in THF (10 mL) at r.t. The reaction mixture was stirred for 3 h, 
after which time, TLC showed complete consumption of the starting material. H2O (1 
mL, 55.55 mmol) was added and the reaction mixture was stirred for a further 1 h. 
The volatiles were then removed under reduced pressure and the resulting mixture 
was azeotroped with dry toluene (3 × 5 mL) to remove any residual H2O. The crude 
amine 72 was used in the next step  without further purification as a stock solution 0.1 
M in CH2Cl2.
Bromide 74 (0.18 mmol, 85 mg) was dissolved in THF (1.8 mL) and treated with 2 
equivalents of TMSN3 (1 M, 0.36 mmol, 360 μL) followed by the addition of 1.5 equiv 
of Py.xHF (70 wt. % HF, 0.27 mmol, 5μL). The reaction mixture was stirred at r.t. for 
15 min after which time the temperature was brought up to 45 °C. After 24 h, mass 
spectral analysis of the reaction mixture showed that the reaction was complete. The 
volatiles were removed under reduced pressure and the crude α-azido carboxylic 
acid 73 (80 mg, 0.18 mmol) was dissolved in CH2Cl2 (1.5 mL). EDC.HCl (35 mg, 0.18 
mmol) was added to the solution at r.t. and the resulting reaction mixture was stirred 
for 10 min. A solution of the crude amine 72 (0.1 M, 0.20 mmol, 200 μL) was then 
added. The mixture was stirred for 6 h. Silica gel (500 mg) was added to the reaction 
mixture and the suspension was stirred for 10 min, after which time, the resulting 
slurry was applied directly on to a silica gel column and eluted with 20% EtOAc in 
hexanes yielding the amide 71 as a white solid (105 mg, 60% from 48, approx. 
1:1:1:1 mixture of four diastereoisomers). Data on the diastereoisomeric mixture: Rf = 
0.2 (20% EtOAc in hexanes); νmax (film)/cm-1 3583w, 3299br (NH), 2921s (CH), 2852s 
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(CH), 2105m (N3), 1652m (C=O), 1545w, 1465s, 1377m, 1246w, 1220w, 1068w, 
758w, 721w, 698w, 665w; δH (300 MHz) 0.88 (6H, app. t, J 6.9, 2 × CH2CH3), 
1.16-1.56 (76H, stack), 1.73-1.92 (2H, stack), 2.08-2.16 (1H, stack), 3.55-4.00 (8H, 
stack), 4.04-4.26 (4H, stack), 5.96-5.97 (1H, stack, PhCH), 6.42- 6.54 (1H, stack, 
CHNHCO), 7.37-7.43 (3H, stack, Ph), 7.46-7.50 (2H, stack, Ph); δC (75 MHz) 14.1 
(CH3, CH2CH3), 22.7 (CH2), 25.3 (CH2), 25.4 (CH2), [25.6 (CH3, CCH3), 25.7 (CH3, 
CCH3)], 26.5 (CH2), 26.6 (CH2), [27.9 (CH3, CCH3), 28.0 (CH3, CCH3)], 29.0 (CH2), 
29.1 (CH2), 29.2 (CH2), 29.27 (CH2), 29.34 (CH2), 29.4 (CH2), 29.6 (CH2), 29.7 (CH2), 
31.9 (CH2), 32.0 (CH2), 32.1 (CH2), 32.2 (CH2), 48.27 (CH), 48.33 (CH), 48.48 (CH), 
48.54 (CH), 56.4 (CH), 62.50 (CH2), 62.55 (CH2), 62.58 (CH2), 62.64 (CH2), 64.1 
(CH), 64.2 (CH), 64.4 (CH), 64.5 (CH), 71.3 (CH2), 71.4 (CH2), 75.8 (CH), 75.9 (CH), 
76.0 (CH), 76.87 (CH), 76.92 (CH), 77.0 (CH), 77.4 (CH), 77.57 (CH), 77.67 (CH), 
77.75 (CH), 77.82 (CH), 79.3 (CH), 79.4 (CH), 79.8 (CH), 79.9 (CH), 103.84 (CH, 
PhCH), 103.87 (CH, PhCH), 103.89 (CH, PhCH), 108.07 (quat. C, C(CH3)2), 108.00 
(quat. C, C(CH3)2), 108.16 (quat. C, C(CH3)2), 108.19 (quat. C, C(CH3)2), 126.5 (CH, 
Ph), 128.35 (CH, Ph), 128.41 (CH, Ph), 129.45 (CH, Ph), 129.52 (CH, Ph), 137.2 
(quat. C, ipsoPh), 168.85 (quat. C, NHCO), 168.89 (quat. C, NHCO), 169.0 (quat. C, 
NHCO), 170.2 (quat. C, NHCO); some resonance overlap; m/z (TOF ES+) 991.7 ([M
+Na]+, 100%); HRMS m/z (TOF ES+) 991.7795 ([M+Na]+. C58H104N4O7Na requires 
991.7803).
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6.16. 1-O - [L- threi tol ] -2- (α -azido-hexacosanoyl)amino-1,3,4-D-r ibo-
octadecantriol 70
Ce(OTf)3 (36.4 mg, 0.062 mmol) was added to a solution of bis-acetal 71 (100 mg, 
0.103 mmol) in 4:1 CH2Cl2/MeNO2 (1 mL). The resulting mixture was stirred for 2 h 
after which time, TLC showed complete disappearance of the starting material. The 
mixture was applied directly on to a silica column and eluted with a solvent gradient 
from CH2Cl2 to 9:1 CHCl3/MeOH to provide the pentaol 70 as a white solid (69 mg, 
80%, 1:1 mixture of diastereoisomers). Data on the mixture: Rf = 0.35 (10% MeOH in 
CHCl3); mp. 109-110 °C; ν max(neat disc)/cm-1: 3303br w (OH, NH), 2914s, 2849s, 
2450br w, 2101m (N3), 1655m (C=O), 1470m, 1446m, 1271w, 1115m, 1073m, 942m, 
719m; δH (CDCl3 / CD3OD 2:1, 300 MHz) 0.82 (6H, app. t, J 6.8, CH2CH3), 1.19-1.61 
(72H, stack), 1.69-1.85 (1H, stack, N3CHCO), 3.50-3.85 (11H, stack), 4.14 (1H, 
stack); δC (75 MHz) 13.9 (CH3, CH2CH3), 22.5 (CH2), 25.4 (CH2), 25.77 (CH2), 25.82 
(CH2), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 29.5 (CH2), 29.6 (CH2), 31.78 (CH2), 31.84 
(CH2), 31.9 (CH2), 32.3 (CH2), 32.4 (CH2), 49.8 (CH, CHN3), 55.6 (CH, CHOH), 63.6 
(CH2, CH2OH), 63.8 (CH, CHOH), 70.1 (CH2, CH2OH), 71.6 (CH, CHOH), 72.3 (CH, 
CHOH), [72.6 (CH2, CH2OH), 72.7 (CH2, CH2OH)], 74.5 (CH, CHOH), [169.97 (quat. 
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C, NHCO), 170.00 (quat. C, NHCO)], some resonance overlap; m/z (TOF ES-) 841.0 
([M]-, 100%), 812.0 (70); HRMS m/z (TOF ES-) 839.7195 ([M]-. C48H95N4O7 requires 
839.7201).
6.17. 2-(2-(2-(Prop-2-ynyloxy)ethoxy)ethoxy)ethanol 87[150]
nBuLi (2.5 M in hexanes, 5.33 mL, 13.33 mmol) was added dropwise over 30 min to a 
cooled (0 °C) solution of triethylene glycol (2.00 g, 13.3 mmol) in THF (100 mL). The 
solution was stirred for 30 min before adding propargyl bromide (80% v/w in toluene, 
1.78 mL, 15.9 mmol) over 15 min. The reaction mixture was allowed to warm to r.t. 
and stirred for 12 h and then quenched by the addition of H2O (100 mL) and Et2O 
(200 mL). The phases were separated. The aqueous phase was extracted with 
CHCl3 (3 × 200 mL). The CHCl3 extracts were combined and the volatiles were 
removed under reduced pressure to provide alcohol 87 as a colourless oil (630 mg, 
25%). Data: Rf = 0.35 (eluent: 35% EtOAc in hexanes); νmax (film)/cm-1 3415br (OH), 
3281br (-CC-H), 2876s, 2116m (C≡C), 1719m, 1642m, 1457m, 1350m, 1299m, 
1248m, 1094br, 935m, 885m, 838m; δH (300 MHz) 2.37 (1H, t, J 6.0, OH), 2.43 (1H, 
t, J 2.3, CH2CCH), 3.60-3.79 (12H, stack), 4.21 (2H, d, J 2.3, CH2CCH), δC (75 MHz) 
57.9 (CH2), 61.1 (CH2), 68.6 (CH2), 69.83 (CH2), 69.86 (CH2), 70.1 (CH2), 72.1 (CH2), 
OHOOO
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74.1 (CH, CH2CCH), 79.2 (quat. C, CH2CCH), the spectroscopic data agree with 
those of the lit.;[150] attempts to obtain mass spectral data (ES, EI) were unsuccessful.
6.18. 3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)pro-1-yne 86[151]
DBU (873 µL, 5.84 mmol) was added dropwise over 10 min to a stirred solution of 
BNPPA (2.13 g, 5.84 mmol) and alcohol 87 (1.00 g, 5.33 mmol) in toluene (5.3 mL). 
The mixture was stirred at r.t. for 12 h after which time TLC showed complete 
consumption of starting material. The reaction mixture was diluted with EtOAc (20 
mL) and quenched with NaHCO3 solution (20 mL). The phases were separated and 
the aqueous layer was extracted with EtOAc (2 × 40 mL). The combined organic 
fractions were washed with NaHCO3 solution (2 × 20 mL), then with brine (20 mL) 
and dried with MgSO4, filtered and the solvent was removed under reduced pressure. 
The residue was partially  purified by flash column chromatography. The azide 
product was contaminated with para-nitrophenol (yellowish-green oil) and was used 
in the next reaction without further purification.
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The crude azide 88 from the previous step  was dissolved in THF/H2O (10 mL, 20:1) 
and treated with Me3P (1 M in THF, 584 µL, 5.84 mmol). The mixture was stirred for 4 
h, after which time, the volatiles were removed under reduced pressure. The residue 
was dissolved in CH2Cl2 (10 mL) and washed with hydrochloric acid (0.1 N, 2 × 10 
mL). The aqueous phase was extracted with CH2Cl2 (2 × 10 mL) and then basified to 
pH = 11 with 1 M NaOH solution. The basic aqueous phase was then back extracted 
with CH2Cl2 (3 × 10 mL). The volatiles were evaporated under reduced pressure to 
provide amine 86 as a colourless oil (550 mg, 55%). Data: νmax (film)/cm-1 3376br 
(NH2), 3251br (-CC-H), 2871s, 2112m (C≡C), 1578s, 1474s, 1351s, 1309m, 1098br, 
1032m, 838w; δH (300 MHz) 2.41 (1H, t, J 2.4, C(1)H), 2.85 (2H, t, J 5.2, C(10)H), 
3.50 (2H, t, J 5.3, C(9)H), 3.60-3.72 (10H, stack), 4.20 (2H, d, J 2.4, C(3)H); δC (75 
MHz) 41.3 (CH2), 58.1 (CH2), 68.8 (CH2), 69.9 (CH2), 70.1 (CH2), 70.3 (CH2), 72.8 
(CH2), 74.4 (CH, CH2CCH), 79.3 (quat. C, CH2CCH), the spectroscopic data agree 
with those of the lit.;[151] attempts to obtained mass spectral data (ES, EI) were 
unsuccessful.
6.19. 3-(2-(2-(2-Amide-D-biotin-ethoxy)ethoxy)ethoxy)pro-1-yne 85
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Et3N (438 µL, 3.68 mmol) was added to a suspension of D-(+)-biotin (300 mg, 1.23 
mmol) in DMF (10 mL) at 0 °C and the mixture was stirred until the suspension 
became a clear solution. At this time, pentafluorophenol trifluoroacetate (344 mg, 
1.23 mmol) was added via syringe. The mixture was stirred for 4 h after which time 
TLC showed complete formation of the ester. The reaction vessel was cooled to 0 °C 
and a solution of amine 86 (230 mg, 1.23 mmol) in DMF (2 mL) was added. The 
resulting solution was stirred for 12 h. The solvent and pentafluorophenol were 
evaporated under reduced pressure (40 °C  at 0.1 mbar). The resulting amorphous 
solid was dissolved in CHCl3 / MeOH (20:1, 5 mL) and applied directly on to a silica 
column (eluent: gradient from 20:1 to 9:1 CHCl3/CH3OH) to provide the amide 85 as 
a colourless paste (356 mg, 70%). Data: Rf = 0.4 (eluent: 5% MeOH in CHCl3); νmax 
(film)/cm-1 3306s, 3017s, 2928s, 2251w (C≡C), 1701s (C=O), 1654m (C=O), 1524m, 
1459m, 1349w, 1331w, 1215s, 1096m, 1032w, 909s, 758s, 668s; δH (300 MHz, 
CDCl3) 1.38 (2H, app. quintet, J 7.2, C(14)H), 1.57-1.73 (4H, stack, C(15)H, C(13)H), 
2.17 (2H, t, J 7.6, C(12)H), 2.43 (1H, t, J 2.2, C(1)H), 2.68 (1H, app. d, J 12.7, 
C(22)Ha), 2.84 (1H, dd, J 12.7, 4.8, C(22)Hb), 3.08-3.15 (1H, m, C(16)H), 3.37-3.41 
(2H, m, C(9)H), 3.51 (2H, t, J 5.1, C(8)H), 3.56-3.59 (4H, stack, C(6)H, C(7)H), 
3.60-3.65 (4H, stack, C(5)H, C(4)H), 4.14 (2H, d, J 2.2, C(3)H), 4.24-4.26 (1H, m, 
C(17)H), 4.43-4.46 (1H, m, C(21)H), 6.05 (1H, s, C(20)H), 6.81 (1H, s, C(18)H), 6.85 
(1H, t, J 5.4, C(10)H); δC (CDCl3, 125 MHz) 25.5 (CH2, C(13)), 27.97 (CH2, C(15)), 
28.20 (CH2, C(14)), 35.8 (CH2, C(12)), 39.0 (CH2, C(9)), 40.40 (CH2, C(22)), 55.6 
(CH, C(16)), 58.2 (CH2, C(3)), 60.1 (CH, C(21)), 61.6 (CH, C(17)), 68.9 (CH2, C(4)), 
69.80 (CH2, C(8)), 69.87 (CH2, C(7)), 70.10 (CH2, C(5)), 70.21 (CH2, C(6)), 74.6 (CH, 
C(1)), 79.4 (quat. C, C(2)), 164.2 (quat. C, C(19)), 173.3 (quat. C, C(11)); m/z (TOF 
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ES+) 436.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 436.1869 ([M+Na]+. 
C19H31N3O5NaS requires 436.1882).
6.20. 1 -O - [L -Thre i to l ] -2 - (25- [4 - (1 -methy lene-10-N -amide-D-b iot in -
triethyleneglycol)-1,2,3-triazole]-hexacosanoyl)amino-1,3,4-D-ribo-
octadecantriol 84
CuSO4.5H2O (296 µg, 1.2 µmol) and ascorbic acid (405 µg, 2.3 µmol) were added to 
a solution of alkyne 85 (4.87 mg, 11.8 µmol) and azide 70 (10 mg, 11.8 µmol) in THF/
H2O/MeOH (1 mL, 5:5:2). The mixture was stirred vigorously  for 12 h at r.t and a 
further 12 h at 40 °C. H2O (5 mL) was added to the mixture and the precipitate was 
collected by  filtration and purified by chromatography on silica gel (eluent: 10% 
MeOH in CHCl3) to provide triazole 84 as a white solid (11 mg, 74%). Data: Rf = 0.3 
(eluent: 15% MeOH in CHCl3); δH (500 MHz, CDCl3/CD3OD 2:1) 0.76 (6H, t, J 6.5, 
CH2CH3), 1.05-1.20 (72H, stack), 1.31-1.35 (2H, stack), 1.45-1.63 (6H, stack), 2.62 
(1H, d, J 12.8, SCHaHb), 2.81-2.86 (1H, m, SCHaHb), 3.05-3.11 (1H, m, SCH), 
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Chemical Formula: C67H127N7O12S
Molecular Weight: 1254.83
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335-3.69 (22H, stack), 4.03-4.07 (1H, m), 4.19-4.23 (1H, m, NHCHCH), 3.37-4.39 
(1H, m, NHCHCH2), 4.55-4.56 (2H, m, CCH2O), 5.18 (1H, app. q, J 8.2, COCHN), 
7.84 (0.5H, s, NCHC), 7.85 (0.5H, s, NCHC); 13C NMR were measured but the signal 
to noice ratio was too poor to allow accurate reporting of the 13C resonances; HRMS 
m/z (TOF ES+) 1276.8325 ([M+Na]+. C67H127N7O12SNa) requires 1276.8305).
6.21. Ethyl 2,3,4,6-tetra-O-acetyl-1-thio-α-D-galactopyranoside 102[152, 153]
To a solution of peracetylated galactose (10.0 g, 25.60 mmol) and ethanethiol (2 mL, 
26.90 mmol) in CH2Cl2 (250 mL) was added BF3.OEt2 (3.8 mL, 30.70 mmol) at 0 °C 
dropwise over 10 min with stirring. The reaction mixture was allowed to warm to r.t. 
and then stirred for 12 h, after which time, when TLC analysis showed the 
disappearance of the starting material. The reaction mixture was then diluted with 
CH2Cl2 (250 mL) and washed with NaOH solution (1 M, 2 × 250 mL). The organic 
extracts were then washed with hydrochloric acid (1 M, 1 × 100 mL). The combined 
organic phases were evaporated under reduced pressure to afford thiogalactoside 
102 as a 1:1 mixture of anomers (9.2 g, 91%). Pure α-anomer was obtained by 
recrystallisation from a mixture of hexanes and EtOAc (4.1 g, 45% based on crude). 
Data: Rf = 0.45 (eluent: 50% ethyl acetate in hexanes); mp 106 – 107 °C; [α]24D + 216 
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(c = 1.0, CHCl3) [lit. [α]24D + 210 (c = 1.0, CHCl3)];[152] νmax (film)/cm-1 2966w (br), 
1750s (C=O), 1740s (C=O), 1367w 1209s, 1116w, 1078m, 1048s, 1007m, 974m, 
911s, 836w, 792w; δH (300 MHz, CDCl3) 1.28 (3H, t, J 6.5, SCH2CH3), 2.00 (3H, s, 
CH3CO), 2.05 (3H, s, CH3CO), 2.08 (3H, s, CH3CO), 2.15 (3H, s, CH3CO), 2.56 (2H, 
m, SCH2), 4.11 (2H, d, J 6.6, (C6)H), 4.60 (1H, app. t, J 6.6, (C5)H), 5.22 (1H, dd, J 
10.9, 3.1, (C3)H), 5.28 (1H, dd, J 10.9, 5.4, (C2)H), 5.46 (1H, d, J 3.1, (C4)H), 5.76 
(1H, d, J 5.4, (C1)H); δC (75 MHz, CDCl3) 14.7 (CH3, SCH2CH3), 20.6 (CH3), 20.8 
(CH3), 24.0 (SCH2CH3), 61.7 (CH2, C6), 66.4 (CH), 67.9 (CH), 68.2 (CH), 81,9 (CH, 
C1), 169.8 (quat. C, CH3CO), 170.1 (quat. C, CH3CO), 170.3 (quat. C, CH3CO), 
some resonance overlap for the acetate signals and for CHs in galactose; m/z (TOF 
ES+) 415.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 415.1042 ([M+Na]+. 
C16H24O9NaS requires 415.1042); the spectroscopic data could not be directly 
compared to those of the lit. as they were measured in DMSO.[152, 153]
6.22. Ethyl 2,3,4,6-tetra-O-benzyl-1-thio-α-D-galactopyranoside 104[152, 153]
To a solution of thiogalactoside 102 (4.0 g, 10.20 mmol) in MeOH (50 mL) was added 
NaOMe (25 wt. % in MeOH, 114 μL, 0.5 mmol) at r.t. The reaction mixture was stirred 
for 2 h, after which time, TLC showed that all of the starting material had been 
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Chemical Formula: C36H40O5S
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consumed. The appearance of a single more polar spot (Rf = 0.15 (eluent: 25% 
MeOH in CHCl3)) indicated the successful formation of the tetraol. Dowex® 50WX8 
(H+, 100-200 mesh, 2.0 g) was then added until the pH of the reaction mixture was 
neutral. The resin was filtered and the filtrate was evaporated under reduced 
pressure to afford the crude tetraol 103. To a solution of the crude tetraol 103 in DMF 
(50 mL) was added NaH (60% in mineral oil, 1.8 g, 44.90 mmol) in 3 portions at 0 °C. 
The resulting mixture was stirred for 30 min, allowing the reaction mixture to warm to 
r.t. BnBr (5.33 mL, 44.90 mmol) was added dropwise over 5 min at 0 °C. The 
resulting mixture was then stirred for 4 h, after which time, TLC  showed that the 
reaction was complete. The reaction mixture was diluted with Et2O (50 mL) and 
quenched with H2O (50 mL). The phases were separated and the aqueous phase 
was extracted with Et2O (2 × 50 mL). The combined organic phases were evaporated 
under reduced pressure and the residue was purified by column chromatography to 
provide thiogalactoside 104 as a clear oil (5.10 g, 85%). Data: Rf = 0.25 (eluent: 10% 
EtOAc in hexanes); νmax (film)/cm-1 3066w, 3030w, 2926w (br), 2865w (br), 1703w 
(br), 1496w, 1453m, 1359m, 1262w (br), 1207w, 1089s (br) 1027s, 910w; δH (300 
MHz, CDCl3) 1.31 (3H, t, J 6.6, SCH2CH3), 2.65-2.81 (2H, m, SCH2CH3), 3.51-3.62 
(4H, stack), 3.83 (1H, t, J 9.6), 3.96 (1H, d, J 2.7), 4.38-4.48 (3H, stack), 4.62 (1H, d, 
J 11.7, CHaHbPh), 4.73 (2H, s, CH2Ph), 4.80 (1H, d, J 9.8, CHcHdPh), 4.88 (1H, d, J 
9.8, CHcHdPh), 4.95 (1H, d, J 11.7, CHaHbPh), 7.19-7.42 (20H, stack, Ph); δC (75 
MHz, CDCl3) 15.0 (CH3, SCH2CH3), 24.6 (CH2, SCH2CH3), 68.7 (CH2), 73.4 (CH2), 
73.5 (CH), 74.3 (CH2), 75.6 (CH2), 77.3 (CH), 78.3 (CH), 84.0 (CH), 85.2 (CH), 126.4 
(CH, Ph), 126.5 (CH, Ph), 126.6 (CH, Ph), 126.7 (CH, Ph), 126.8 (CH, Ph), 126.9 
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(CH, Ph), 127.0 (CH, Ph), 127.2 (CH, Ph), 127.3 (CH, Ph), 137.7 (quat. C, ipsoPh) 
138.23 (quat. C, ipsoPh), 138.26 (quat. C, ipsoPh), 138.6 (quat. C, ipsoPh), some 
resonance overlap  on the aromatic region; m/z (TOF ES+) 607.3 ([M+Na]+, 100%); 
HRMS m/z (TOF ES+) 607.2491 ([M+Na]+. C36H40O5NaS requires 607.2494); the 
spectroscopic data could not be compared to those of the lit. as they  were measured 
in DMSO.[152, 153]
6.23. 2,3,4,6-Tetra-O-benzyl-(α,β)-D-galactopyranose 105[143, 144]
To a solution of thiogalactoside 104 (5.0 g, 8.55 mmol) in acetone (50 mL) was added 
NIS (4.8 g, 21.37 mmol). The brownish-red reaction mixture was stirred for 30 min, 
after which time, TLC  showed that all the starting material was consumed. CH2Cl2 
(100 mL) was added and Na2S2O3·5H2O (approx. 300 mg) was then added until the 
colouration disappeared H2O (50 mL) was then added. The phases were separated 
and the aqueous phase was extracted with CH2Cl2 (2 × 50 mL). The combined 
organic phases were evaporated under reduced pressure and the residue was 
purified by column chromatography to provide the hemiacetal 105 as a colourless oil 
(3.5 g, 75%, α/β ratio = 1:1). Data on the diastereomeric mixture: Rf = 0.15 (eluent: 
25% EtOAc in hexanes); νmax (film)/cm-1 3414w (br), 3030w, 2920w (br), 2867w (br), 
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2248w (br), 1496w (s), 1453m (s), 1363w (br), 1208w, 1092s (br), 1060s (br), 1027m, 
908s (s), 730s (s); δH (300 MHz, CDCl3) 2.93 (0.5H, d, J 2.0, CHOH), 3.15 (0.5H, d, J 
6.2, CHOH), 3.45-3.61 (3H, stack), 3.76 (0.5H, dd, J 9.5 , 7.4), 3.88-4.06 (2H, stack), 
4.38-4.50 (2H, stack), 4.56-4.85 (5.5H, stack), 4.90-4.96 (1.5H, stack), 5.27-5.29 
(0.5H, stack), 7.23-7.39 (20H, stack, Ph); δC (75 MHz, CDCl3) 69.0 (CH2), 69.2 (CH2), 
69.5 (CH), 73.1 (CH2), 73.4 (CH2), 73.5 (CH2), 73.6 (CH2), 73.7 (CH), 74.6 (CH2), 
74.7 (CH2), 74.9 (CH), 75.2 (CH2), 76.6 (CH), 78.8 (CH), 80.8 (CH), 82.3 (CH), 91.9 
(CH), 97.8 (CH), 127.62 (CH, Ph), 127.67 (CH, Ph), 127.71 (CH, Ph), 127.78 (CH, 
Ph), 127.83 (CH, Ph), 127.88 (CH, Ph), 127.9 (CH, Ph), 128.11 (CH, Ph), 128.17 
(CH, Ph), 128.2 (CH, Ph), 128.34 (CH, Ph), 128.38 (CH, Ph), 128.42 (CH, Ph), 
128.47 (CH, Ph), 128.53 (CH, Ph), 128.59 (CH, Ph), 137.8 (quat. C, ipsoPh), 137.9 
(quat. C, ipsoPh), 138.4 (quat. C, ipsoPh), 138.5 (quat. C, ipsoPh), 138.63 (quat. C, 
ipsoPh), 138.68 (quat. C, ipsoPh), 138.8 (quat. C, ipsoPh), some resonance overlap 
in the aromatic region, and in the CHOH and CH2OH region; m/z (TOF ES+) 563.3 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 563.2396 ([M+Na]+. C34H36O6Na requires 
563.2410); the spectroscopic data agree with that of commercially available material 
and lit.[143, 144]
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6.24. 3-O - [2,3,4,6-Tetra-O -benzyl-(α ,β)-D-galactopyranoside]-1,2-O -
isopropylidene-syn-glycerol 106ii
To a solution of hemiacetal 105 (400 mg, 0.74 mmol) in CH2Cl2 (6.4 mL) was added 
Ph3P (582 mg, 2.22 mmol) and CBr4 (736 mg, 2.22 mmol). The reaction mixture was 
stirred for 3 h after which time, TLC  showed that most of the starting hemiacetal was 
converted to the glycosyl bromide. Activated 4Å MS (200 mg) were added to the 
reaction mixture and stirring was continued for 5 min followed by  the sequential 
addition of iPr2EtN (322 μL, 1.85 mmol), TMU (533 μL, 4.44 mmol) and Et4NBr (466 
mg, 2.22 mmol). The reaction mixture was stirred for 5 min before a solution of 
alcohol 93 (293 mg, 276 μL, 2.22 mmol) in CH2Cl2 (1.0 mL) was added dropwise 
over 10 min. The reaction mixture was then stirred for 12 h after which time, TLC 
showed the reaction was complete. The reaction mixture was diluted with toluene (10 
mL), which caused the precipitation of Ph3PO. The precipitate was filtered and the 
Ph3PO rinsed with toluene (10 mL). The filtrate was washed with water (2 × 10 mL) 
and the aqueous phase was extracted with toluene (2 × 10 mL). The combined 
organic phases were evaporated under reduced pressure and the residue was 
purified by column chromatography to provide the glycoside 106ii as a colourless oil 
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(considerable resonance overlap  in the 1H NMR spectrum of both crude and purified 
products prevented an accurate measurement of the α/β ratio; therefore an estimate 
was obtained from the crude 13C  NMR spectrum, α/β  ratio = 10:1) (412 mg, 85%). 
Data for the α-anomer: Rf = 0.35 (eluent: 25% EtOAc in hexanes); νmax (film)/cm-1 
3030w, 2985w, 2871w (br), 1497w, 1454w, 1254w, 1210w, 1156w, 1095s, 1052s, 
1028s, 911w, 841w; δH (500 MHz, CDCl3) 1.41 (3H, s, C(CH3)2), 1.46 (3H, s, 
C(CH3)2), 3.60 (2H, app. d, J 6.3, C(6)H), 3.64 (1H, dd, J 10.7 and 5.7, C(3')Ha), 3.68 
(1H, dd, J 10.7, 5.8, C(3')Hb), 3.79 (1H, dd, J 8.3, 6.3, C(1')Ha), 3.99 (1H, dd, J 9.4, 
2.7, C(3)H), 4.02-4.04 (2H, stack, C(4)H, C(5)H), 4.10 (1H, dd, J 8.2, 6.3, C(1')Hb), 
4.12 (1H, dd, J 9.4, 3.6, C(2)H), 4.41 (1H, app. t, J 5.9, C(2')H), 4.46 (1H, d, J 11.8, 
C(10)Ha), 4.53 (1H, d, J 11.8, C(10)Hb), 4.65 (1H, d, J 11.5, C(9)Ha), 4.74 (1H, d, J 
12.0, C(7)Ha), 4.79 (1H, d, J 11.7, C(8)Ha), 4.87 (1H, d, J 12.0, C(7)Hb), 4.90 (1H, d, 
J 11.7, C(8)Hb), 4.99 (1H, d, J 3.6, C(1)H), 5.02 (1H, d, J 11.5, C(9)Hb), 7.29-7.45 
(20H, stack, Ph); δC (125 MHz, CDCl3) 25.4 (CH3, C(CH3)2), 26.6 (CH3, C(CH3)2), 
66.8 (CH2, C1'), 68.88 (CH2, C6), 68.96 (CH2, C3'), 69.4 (CH, C5), 73.0 (CH2, C7, 
C8), 73.3 (CH2, C10), 74.5 (CH, C2'), 74.6 (CH2, C9), 74.9 (CH, C4), 76.4 (CH, C2), 
78.7 (CH, C3), 98.0 (CH, C1), 109.2 (quat. C, C(CH3)2), 127.3 (CH, Ph), 127.40 (CH, 
Ph), 127.46 (CH, Ph), 127.53 (C, Ph), 127.6 (CH, Ph), 127.7 (CH, Ph), 128.06 (CH, 
Ph), 128.07 (CH, Ph), 128.15 (CH, Ph), 128.18 (CH, Ph),128.22 (CH, Ph), 137.8 
(quat. C, ipsoPh), 138.51 (quat. C, ipsoPh), 138.53 (quat. C, ipsoPh), 138.7 (quat. C, 
ipsoPh), some resonance overlap in the aromatic region; m/z (TOF ES+) 677.2 ([M
+Na]+, 100%); HRMS m/z (TOF ES+) 677.3087 ([M+Na]+. C40H46O8Na requires 
677.3090).
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6.25. 3-O-[2,3,4,6-Tetra-O-(chloroacetyl)-α-D-galactopyranoside]-1,2-O-
isopropylidene-syn-glycerol 108
To a solution of the benzyl ether-protected galactoside 106ii (650 mg, 0.99 mmol) in 
DMF (10 mL) was added Pd/C (10 wt. %, 105 mg, 99 μmol). The reaction vessel was 
flushed twice with H2 before being filled with H2 and stoppered. The progress of the 
reaction was monitored by TLC until the disappearance of the starting material and 
formation of a new product indicating that the tetraol 107 was formed, Rf = 0.15 
(eluent: 10% MeOH in CHCl3). The charcoal was filtered and the filtrate was 
evaporated under reduced pressure. The residue was purified by flash column 
chromatography to provide the tetraol 107 as a syrup, which was dissolved in 
pyridine (10 mL). The resulting solution was treated with chloroacetic anhydride (745 
mg, 4.36 mmol). After 10 min, TLC  showed that the starting tetra-ol was consumed 
and a single new product formed. The reaction mixture was diluted with CH2Cl2 (20 
mL) and quenched with H2O (20 mL). The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (2 × 10 mL). The combined organic phases were 
evaporated under reduced pressure and the residue was purified by column 
chromatography to provide chloroacetylated galactoside 108 as a colourless oil (356 
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mg, 60%). Data: Rf = 0.35 (eluent: 50% EtOAc in hexanes); δH (500 MHz, CDCl3) 
1.36 (3H, s, C(CH3)2), 1.41 (3H, s, C(CH3)2), 3.52 (1H, dd, J 11.1, 6.3, C(3')Ha), 3.68 
(1H, dd, J 8.5, 6.0, C(1')Ha), 3.75 (1H, dd, J 11.1, 4.1, C(3')Hb), 3.97 (2H, s, C(11)H), 
4.043 (1H, app. t, J 6.8, C(1')Hb), 4.046 (2H, s, C(8)H or C(13)H), 4.07 (2H, d, J 3.5, 
C(8)H or C(13)H), 4.14 (2H, s, C(9)H), 4.23-4.28 (3H, stack, C(6)H, C(2')H), 4.38 
(1H, t, J 6.9, C(5)H), 5.17 (1H, dd, J 10.6, 3.7, C(2)H), 5.27 (1H, d, J 3.7, C(1)H), 
5.48 (1H, dd, J 10.6, 3.4, C(3)H), 5.51 (1H, app. d, J 3.4, C(4)H); δC (125 MHz, 
CDCl3) 25.3 (CH3, CCH3), 26.7 (CH3, CCH3), 40.26 (CH2, C(11)), 40.33 (CH2, C(9)), 
40,38 (CH2, C(8) or C(13)), 40.46 (CH2, C(8) or C(13)), 62.7 (CH2, C(6)), 65.89 (CH2, 
C(1')), 65.98 (CH, C(5)), 68.8 (CH, C(3)), 69.1 (CH, C(2)), 69.6 (CH, C(4)), 69.7 
(CH2, C(3')), 74.6 (CH, C(2')), 96.3 (CH, C(1)), 109.8 (quat. C, C(CH3)2), 166.3 (quat. 
C, C(12)), 166.7 (quat. C, C(14) and C(7)), 17.1 (quat. C, C(10)); m/z (TOF ES+) 
621.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 621.0070 ([M+Na]+. C20H26O12Na35Cl4 
requires 621.0076).
6.26. 3-O-[2,3,4,6-Tetra-O-(chloroacetyl)-α-D-galactopyranoside]-syn-glycerol 
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Chemical Formula: C17H22Cl4O12
Molecular Weight: 560.16
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To a solution of acetal 108 (250 mg, 0.42 mmol) in MeNO2 saturated with H2O (4.2 
mL) was added Ce(OTf)3 (75 mg, 0.13 mmol). The reaction mixture was stirred for 2 
h, after which time, TLC showed the disappearance of the starting material. The 
reaction mixture was diluted with CH2Cl2 (5 mL) and quenched with H2O (5 mL). The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (2 × 5 
mL). The combined organic phases were evaporated under reduced pressure. The 
residue was purified by column chromatography to provide diol 109 (172 mg, 75%) 
as a colourless oil. Data: Rf = 0.20 (eluent: 80% EtOAc in hexanes); δH (300 MHz, 
CDCl3) 1.95-2.01 (1H, m, OH), 2.54 (1H, d, J 4.4, OH), 3.56 (1H, dd, J 10.3, 6.7), 
3.60-3.79 (1H, m), 3.85 (1H, dd, J 10.3, 3.8), 3.90-3.97 (1H, m), 3.99 (2H, s, ClCH2), 
4.08 (4H, s, 2 × ClCH2), 4.16 (2H, s, ClCH2), 4.25-4.33 (3H, stack), 4.42 (1H, t, J 
6.1), 5.20-5.27 (2H, stack), 5.46-5.54 (2H, stack); δC (75 MHz, CDCl3) 40.3 (CH2, 
ClCH2), 40.43 (CH2, ClCH2), 40.45 (CH2, ClCH2), 63.0 (CH2), 63.4 (CH2), 66.0 (CH), 
68.9 (CH), 69.1 (CH), 69.7 (CH), 70.0 (CH2), 70.5 (CH), 96.2 (CH, C1), 166.6 (quat. 
C, CH2CO), 166.8 (quat. C, CH2CO), 167.1 (quat. C, CH2CO), 167.2 (quat. C, 
CH2CO); m/z (TOF ES+) 580.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 580.9769 ([M
+Na]+. C17H22O12Na35Cl4 requires 580.9763).
6.27. Preparation of BbGL-IIc[52, 154]
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Chemical Formula: C43H80O10
Molecular Weight: 757.09
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To a solution of diol 10 (25.0 mg, 44.6 μmol) and oleic acid (12.6 mg, 44.6 μmol) in 
CH2Cl2 (1 mL) was added DCC in CH2Cl2 (1.00 M, 44.6 μmol, 44.6 μL) and DMAP in 
CH2Cl2 (0.5 mg, 4 μmol, 25 μL). The solution was stirred for 2 h after which time TLC 
showed that all the starting diol had been consumed. Palmitic acid in CH2Cl2 (11.4 
mg, 44.6 μmol, 50 μL), DCC in CH2Cl2 (1.00 M, 44.6 μmol, 44.6 μL) and DMAP in 
CH2Cl2 (0.5 mg, 4 μmol, 25 μL) were then added and stirring was continued for 12 h. 
The reaction mixture was diluted with CH2Cl2 (5 mL) and quenched with H2O (5 mL). 
The phases were separated and the aqueous phase was extracted with CH2Cl2 (3 × 
5 mL). The combined organic phases were evaporated under reduced pressure. The 
residue was dissolved in CH2Cl2/MeOH (1:1, 1 mL) and the solution was treated with 
Et3N (1.00 M in H2O, 446 μmol, 446 μL). The reaction mixture was stirred for 2 h 
after which time TLC  showed that the starting material was consumed. The reaction 
mixture was diluted with H2O (5 mL) and the aqueous phase was extracted with 
CHCl3 (3 × 5 mL). The combined organic extracts were evaporated under reduced 
pressure and the residue was purified by column chromatography (eluent: gradient 
from CHCl3 to 10% MeOH in CHCl3) to provide BbGL-IIc (15 mg, 44%) as a 
colourless oil. Data: Rf = 0.45 (eluent: 10% MeOH in CHCl3); δH (300 MHz, CDCl3) 
0.85 (6H, app. t, J 6.4, 2 ×  CH2CH3), 1.18-1.27 (44H, stack), 1.55-1.62 (4H, m), 
1.95-2.01 (4H, m, 2 × CH2CH=CH), 2.29 (4H, app. t, 2 × CH2CO), 3.57-3.63 (1H, m), 
3.72-3.84 (6H, stack), 4.07-4.13 (2H, stack), 4.35 (1H, dd, J 11.9, 3.9), 4.91 (1H, d, J 
3.6, C(1)H), 5.20-5.26 (1H, m, C(2')H), 5.30-5.34 (2H, stack, CH=CH); m/z (TOF ES+) 
780.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 779.5636 ([M+Na]+. C43H80O10Na 
requires 779.5649).
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6.28. Preparation of BbGL-IIf[52, 154]
To a solution of diol 109 (20.0 mg, 35.7 μmol) and linoleic acid (10.0 mg, 35.7 μmol) 
in CH2Cl2 (1 mL) was added DCC in CH2Cl2 (1.00 M, 35.7 μmol, 35.7 μL) and DMAP 
in CH2Cl2 (0.4 mg, 3 μmol, 25 μL). The solution was stirred for 2 h after which time 
TLC showed that all the starting diol had been consumed. Oleic acid in CH2Cl2 (10.2 
mg, 35.7 μmol, 50 μL), DCC in CH2Cl2 (1.00 M, 35.7 μmol, 35.7 μL) and DMAP in 
CH2Cl2 (0.4 mg, 3 μmol, 25 μL) were then added and the stirring was continued for 
12 h. The reaction mixture was diluted with CH2Cl2 (5 mL) and quenched with H2O (5 
mL). The phases were separated and the aqueous phase was extracted with CH2Cl2 
(3 × 5 mL). The combined organic phases were evaporated under reduced pressure. 
The residue was dissolved in CH2Cl2/MeOH (1:1, 1 mL) and the solution was treated 
with Et3N (1.00 M in H2O, 357 μmol, 357 μL). The reaction mixture was stirred for 2 h 
after which time TLC  showed that the starting material was consumed. The reaction 
mixture was diluted with H2O (5 mL) and the aqueous phase was extracted with 
CHCl3 (3 × 5 mL). The combined organic extracts were evaporated under reduced 
pressure and the residue was purified by column chromatography (eluent: gradient 
from CHCl3 to 10% MeOH in CHCl3) to provide BbGL-IIf (11.8 mg, 33%) as a 
colourless oil. Data: Rf = 0.45 (eluent: 10% MeOH in CHCl3); δH (500 MHz, CDCl3) 
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Chemical Formula: C45H80O10
Molecular Weight: 781.11
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0.84 (6H, stack, 2 × CH2CH3), 1.25-136 (34H, stack), 1.58-1.67 (4H, stack), 
1.98-2.05 (8H, stack), 2.29-2.32 (4H, stack), 2.76 (2H, t, J 6.8), 3.62 (1H, dd, J 10.9, 
6.1), 3.73 (1H, dd, J 9.8, 3.2), 3.79-3.85 (4H, stack), 3.89-3.93 (1H, m), 4.05 (1H, d, J 
2.9), 4.11 (1H, dd, J 11.9, 5.8), 4.36 (1H, dd, J 11.9, 4), 4.93 (1H, d, J 3.7), 5.22-5.26 
(1H, m), 5.28-5.40 (6H, stack); m/z (TOF ES+) 803.6 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 803.5635 ([M+Na]+. C45H80O10Na requires 803.5649).
Experimental Section
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